Composition for direct transdifferentiation induction and stem cells treated therewith
A composition inducing CtBP oligomerization directly converts adult stem cells into neural progenitor cells, addressing inefficiencies in current methods by enhancing neural marker expression and neuroregenerative factors, effectively treating neurological diseases.
Patent Information
- Application Number
- JP2024530500
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-11-22
- Filing Date
- 2022-11-21
- Publication Date
- 2024-11-13
- Estimated Expiration
- 2042-11-21
AI Technical Summary
Current methods for inducing transdifferentiation of stem cells into neural progenitor cells are inefficient and face challenges such as low specificity in differentiation factors and risks of teratoma formation, limiting their therapeutic potential for neurological diseases.
A composition comprising compounds of Chemical Formulas 1, 2, and 3 is used to induce oligomerization of CtBPs, directly converting adult stem cells, particularly mesenchymal stem cells, into neural progenitor cells (ciNSC5) by regulating CtBP1 and CtBP2, enhancing expression of neural markers and secretion of growth factors.
The composition significantly increases the expression of neural markers and secretion of neuroprotective and neuroregenerative factors, demonstrating therapeutic efficacy in animal models of ALS, MS, PD, and spinal cord injury, promoting neuroregeneration and functional recovery.
Smart Images

Figure 2024542257000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to a composition that induces direct transdifferentiation through oligomerization of CtBPs, and uses of stem cells treated therewith. [Background technology]
[0002] The nervous system is divided into the central nervous system (CNS) and the peripheral nervous system (PNS). The CNS includes the brain and spinal cord, while the rest of the nervous system is the PNS. The PNS is divided into the somatic nervous system, which includes motor and sensory nerves, and the autonomic nervous system. The neurons, astrocytes, and oligodendrocytes that make up the CNS (brain and spinal cord) can be generated by differentiation of neural stem cells (NSCs) or neural progenitor cells (NPCs) that have differentiated into pluripotent stem cells, while the peripheral nerves (autonomic, motor, and sensory nerves) and Schwann cells that make up the PNS are derived from neural crest stem cells (NCSCs) that have differentiated into pluripotent stem cells. Neurons that make up the nervous tissue play a role in transmitting command signals from the central nervous system to the peripheral nervous system through dendrites and axons, and in transmitting information input from the peripheral nervous system to the central nervous system. Axons transmit electrical signals to neurons farther from the central nervous system and are surrounded by myelin, an insulating structure, to speed up signal transmission; this process is called myelination. Mammalian brains are able to perform complex functions by generating systematic neural networks through a series of processes, including division and differentiation of neural stem cells, survival and death, and synapse formation. Even in adulthood, animal brain neurons produce many substances necessary for neural growth, allowing axons and dendrites to grow, and they can be said to continue to differentiate, as they constantly remodel synaptic connections and neural networks every time new learning and memory is acquired. If nerve cells do not receive target-derived survival factors such as nerve growth factor during the process of cell differentiation and synapse formation, they will die, and cell death due to stress and cytotoxic agents is a major cause of degenerative brain diseases.Unlike the central nervous system, the peripheral nervous system of animals regenerates axons over a long period of time when injured. The axons behind the injured nerve degenerate through a process known as Wallerian degeneration, the cell body of the nerve begins to grow axons again, and Schwann cells divide and then determine the target nerve by survival or death, and then further differentiate, undergoing further developmental processes before regenerating.
[0003] Degenerative neurological diseases are diseases in which the gradual structural and functional loss of nerve cells occurs due to various causes, leading to the degeneration of central nervous system functions such as cognition, movement, and sensation. Degenerative neurological diseases are accompanied by symptoms such as dementia, extrapyramidal abnormalities, cerebellar abnormalities, sensory disorders, and movement disorders due to the progression of nerve cell degeneration in specific parts of the nervous system, and symptoms may also appear in multiple parts at the same time. In response to this, diseases are diagnosed based on the clinical appearance of the patient, but the symptoms are diverse and different diseases often show common clinical symptoms, making diagnosis difficult. In such degenerative neurological diseases, the symptoms appear gradually and often develop with aging. Once the disease develops, the disease progresses continuously for several years or decades until death, and it is difficult to treat fundamentally, resulting in a large social burden. It is known that the cause of the disease is genetic influence due to family influence, but acquired factors also play an important role. Degenerative neurological diseases are broadly classified according to their clinical symptoms into progressive dementia (such as Alzheimer's disease), neurological disorders (such as Pick's disease), posture and movement disorders (such as Parkinson's disease), progressive ataxia, muscle atrophy and weakness, and sensory and motor disorders.
[0004] Multiple sclerosis (MS) is an autoimmune, chronic inflammatory and demyelinating central nervous system disease that occurs in genetically susceptible individuals and is associated with immunological factors such as antibodies, complements, and innate immune response mediators due to environmental factors such as viruses. MS is classified as an inflammatory demyelinating disease and can occur in all age groups, but it is most common in people aged 20 to 40, and the incidence rate in women is known to be about twice as high as in men. This neurological disorder is caused by damage to the myelin sheath that surrounds the axons of nerve cells due to an inflammatory reaction in the central nervous system. Lesions appear in a scattered manner in the white matter of the brain and spinal cord, and it is a primary inflammatory disease, which is a typical phenomenon in the lesion area. In the early stages, inflammation is temporary and the damaged myelin sheath is restored, but it does not last. However, as time passes, pathological changes progress due to widespread activation of microglia associated with intensive and chronic neurodegeneration, and the clinical symptoms of disability become increasingly severe.
[0005] Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is the most fatal progressive neurodegenerative disease characterized by a significant loss of motor neurons in the primary motor cortex, brain stem, and spinal cord. The loss of motor neurons disrupts basic and fundamental movements such as breathing, typically resulting in the patient's death within 2-5 years after diagnosis. The gradual deterioration of the patient's motor function eventually severely impairs the patient's ability to breathe, necessitating some form of respiratory support for the patient's survival. Other symptoms also include muscle weakness of the hands, arms, legs, or swallowing muscles. Some patients (e.g., frontotemporal dementia (FTD)-ALS) may also develop frontotemporal lobe dementia. According to the ALS Association, approximately 5,600 people in the United States are diagnosed with ALS each year. The incidence of ALS is 2 per 100,000. Two forms of ALS have been described: sporadic ALS (sALS), which is the most common form of ALS in the United States, accounting for 90-95% of all diagnosed cases; and familial ALS (fALS), which occurs primarily in familial systems with dominant inheritance and accounts for only about 5-10% of all cases in the United States. sALS and fALS cannot be distinguished clinically. Currently, the glutamate toxicity inhibitor riluzole and the antioxidant edaravone are prescribed in clinical practice, but although the drugs have shown some effect in slowing the progression of ALS, they cannot be expected to have a curative effect. Another strategy for the treatment of ALS is stem cell-based therapy. Stem cells have the potential to differentiate into motor neurons and replace degenerated motor neurons in the central nervous system of ALS patients, e.g., the primary motor cortex, brainstem, and spinal cord. Indeed, stem cells derived from various sources, including induced pluripotent stem cells (iPSCs), mesenchymal stem cells (MSCs) (e.g., bone marrow stromal cells (BMSCs) and adipose-derived stem cells (ASCs)), and neural stem cells of neural tissue origin (e.g., fetal spinal neural stem cells (NSCs), multipotent neural progenitor cells (NPCs)), have been proposed as potential substitutes for degenerated motor neurons during the progression of ALS (see, for example, Kim et al., Exp. Neurobiol., 2014, 23(3), 207-214).
[0006] Parkinson's disease was first reported by James Parkinson in 1817. It is a typical degenerative brain disease that causes loss of motor skills due to loss of nerve cells in the substantia nigra (SN), which secretes dopamine, a neurotransmitter that regulates muscles, and dopamine deficiency in the striatum. Parkinson's disease affects 1% of the population over 65 years old and 5% of the population over 85 years old (Twelves et al., Mov Disord 18, 19-31). Characteristic clinical symptoms include resting tremor, bradykinesia, rigidity, and postural instability, and are caused by selective loss of dopaminergic neurons in the substantia nigra. The presence of intraneuronal proteinous inclusions known as Lewy bodies is a typical pathological feature (Olanow et al., Annu Rev Neurosci 22, 123-44). The exact cause of Parkinson's disease is unknown. In the case of the sporadic form of Parkinson's disease, which is the majority of cases, the cause is idiopathic and almost unknown, but it is assumed that a complex interaction between environmental factors and genetic susceptibility, which has not yet been fully elucidated, is an important cause (Langston et al., Ann Neurol 44(3 Suppl 1):S45-52). Parkinson's disease pathologically manifests as a specific loss of melanin-pigmented dopaminergic neurons and neurite fibers in the substantia nigra of the midbrain and a lack of dopamine in the striatum, which results in abnormal behavioral symptoms. In addition, Lewy bodies, which are protein aggregates, are observed in the neurons of Parkinson's disease patients as a marker of the disease.Representative pathogenic mechanisms of Parkinson's disease include oxidative stress, mitochondrial dysfunction, ubiquitin-proteasome dysfunction, and accumulation of misfolded proteins.
[0007] When the spinal nerves are damaged by trauma, it leads to paralysis of the human body. Although the structure of the spinal nerve tissue is simpler than that of the brain, it is not easy to regenerate. Pathological phenomena that occur after spinal cord injury can be broadly divided into primary injury and secondary injury according to the time. Primary injury occurs within a few minutes after injury, and mainly the cells at the injured site undergo necrosis. At this stage, cells are destroyed so quickly that it is almost impossible to treat with pharmacological treatment. Secondary injury following primary injury progresses slowly over a period of several hours to several days, and not only the cells at the injured site degenerate, but even the surrounding undamaged nerve cells and oligodendrocytes gradually begin to die due to apoptosis. Cell death continues to progress from the injured site, and eventually the damaged area inside the spinal cord gradually expands. In addition, the axon, which is the pathway through which nerve signals travel, and the myelin sheath that helps the axon function degenerate, eventually forming a cystic cavity in the spinal cord, preventing further nerve signal transmission and causing permanent loss of function. Research has been ongoing to prevent or alleviate permanent functional paralysis caused by spinal cord injury through research into the causes and regeneration of the pathological effects that occur after spinal cord trauma for a long time. The initial mechanism of spinal cord injury progresses too quickly to be treated pharmacologically, so it is important to develop therapeutic agents that use pharmacological strategies to treat the secondary mechanisms.
[0008] Up until now, various pharmacological treatments such as steroids, antioxidants, glutamic acid hydrosol inhibitors, ion channel inhibitors, anti-inflammatory agents, and nerve growth factors have been tried, but only methylprednisolone is currently used in clinical practice. However, methylprednisolone has the limitation that it can only be effective if administered within 8 hours after spinal cord injury, and it has anti-inflammatory, antioxidant, and anti-apoptotic effects, reducing secondary damage and causing some recovery, but it has side effects that can cause the risk of infection and gastrointestinal complications, so in fact, there is currently no effective spinal cord injury treatment.
[0009] Until now, the focus has been on developing treatments to reduce the degree of secondary damage that occurs after injury, rather than on nerve regeneration. However, in recent years, as stem cell research has been actively conducted in various fields, the possibility of nerve regeneration therapy for irreversible nervous system damage such as spinal cord injury is gradually increasing.
[0010] Cellular therapy, on the other hand, involves the administration of living cells for any purpose, including, for example, regenerative medicine, organ transplantation, and even for the diagnosis or prevention of any condition, such as cancer. Stem cells have been evaluated as having great potential in cell therapy. Stem cells are cells that can differentiate into various cells that make up biological tissues, and are a collective term for undifferentiated cells that can be obtained from embryonic, fetal, and adult tissues before differentiation. Stem cells differentiate into specific cells depending on a differentiation stimulus (environment), and unlike cells that have completed differentiation and stopped dividing, they can produce identical cells through cell division (self-renewal), have the property of proliferation (expansion), and can differentiate into other cells depending on a different environment or other differentiation stimuli, so they are characterized by their plasticity in differentiation. Stem cells are broadly classified into embryonic stem cells (ES cells) that are derived from embryos and have the potential to differentiate into all types of cells, and adult stem cells that are derived from various tissues and have the potential to differentiate into multiple types of cells. Adult stem cells include hematopoietic stem cells, mesenchymal stem cells (MSCs), neural stem cells (NSCs), intestinal stem cells, muscle stem cells, hair follicle stem cells, and endothelial stem cells. Among these, mesenchymal stem cells are well known to exist in many mature tissues and have the ability to self-renew and differentiate into various lineages. They can be easily obtained from adult tissues such as bone marrow, adipose tissue, placenta, umbilical cord blood, and Wharton's jelly.
[0011] In order to overcome the limitations of conventional differentiation into specific cells using induced pluripotent stem cells and cell therapy through this, much research has been conducted on direct conversion, a technology that reverse-differentiates any somatic cell into induced pluripotent stem cells that can differentiate into all cells, and then directly converts them into the desired specific cells without going through the process of further differentiation (re-differentiation). However, the existing direct conversion method has various problems. For example, the cross-differentiation method using pluripotent stem cells formed in the reverse differentiation stem cell induction process can induce various tissue cells, but it contains the risk of teratoma formation. The differentiation method using the gene combination of reverse differentiation stem cell factors and specific tissue cell-specific transcription factors discovered has a low risk of teratoma formation, but it is difficult to discover specific factors that induce each tissue cell differentiation. [Prior art documents] [Non-patent literature]
[0012] [Non-Patent Document 1] Kim et al., Exp. Neurobiol., 2014, 23(3), 207-214 [Non-Patent Document 2] Twelves et al., Mov Disord 18, 19-31 [Non-Patent Document 3] Olanow et al., Annu Rev Neurosci 22, 123-44 [Non-Patent Document 4] Langston et al., Ann Neurol 44(3 Suppl 1):S45-52 Summary of the Invention [Problem to be solved by the invention]
[0013] An object of the present invention is to provide a composition for inducing oligomerization of CtBPs (C-terminal binding proteins).
[0014] It is also an object of the present invention to provide a composition for direct transdifferentiation induction.
[0015] It is also an object of the present invention to provide a method for inducing oligomerization of CtBPs.
[0016] It is also an object of the present invention to provide a method for inducing direct trans-differentiation.
[0017] Another object of the present invention is to provide stem cells treated with one or more compounds selected from the group consisting of a compound of Chemical Formula 1, a compound of Chemical Formula 2, and a compound of Chemical Formula 3.
[0018] Another object of the present invention is to provide a pharmaceutical composition for preventing or treating nerve damage diseases, which comprises the stem cells as an active ingredient.
[0019] It is also an object of the present invention to provide a use of a compound of Chemical Formula 1, a compound of Chemical Formula 2 or a compound of Chemical Formula 3 for inducing oligomerization of CtBPs.
[0020] It is also an object of the present invention to provide a use of a compound of formula 1, a compound of formula 2 or a compound of formula 3 for direct transdifferentiation induction.
[0021] Another object of the present invention is to provide a use of stem cells treated with one or more compounds selected from the group consisting of a compound of Chemical Formula 1, a compound of Chemical Formula 2, and a compound of Chemical Formula 3 for preventing or treating nerve damage diseases.
[0022] It is a further object of the present invention to provide a method for treating nerve damage diseases. [Means for solving the problem]
[0023] In order to achieve the above object, the present invention provides a composition for inducing oligomerization of CtBPs, comprising at least one selected from the group consisting of a compound represented by Chemical Formula 1, a compound represented by Chemical Formula 2, and a compound represented by Chemical Formula 3.
[0024] The present invention also provides a composition for directly inducing transdifferentiation of adult stem cells into neural progenitor cells, comprising at least one compound selected from the group consisting of a compound of Chemical Formula 1, a compound of Chemical Formula 2, and a compound of Chemical Formula 3.
[0025] The present invention also provides a method for inducing oligomerization of CtBPs.
[0026] The present invention also provides a method for inducing direct trans-differentiation.
[0027] The present invention also provides stem cells treated with one or more compounds selected from the group consisting of a compound of Chemical Formula 1, a compound of Chemical Formula 2, and a compound of Chemical Formula 3.
[0028] The present invention also provides a pharmaceutical composition for preventing or treating nerve damage diseases, comprising the stem cells, stem cell culture or suspension culture as an active ingredient.
[0029] The present invention also provides a use of a compound of Formula 1, a compound of Formula 2, or a compound of Formula 3 for inducing oligomerization of CtBPs.
[0030] The present invention also provides a use of a compound of formula 1, a compound of formula 2 or a compound of formula 3 for direct transdifferentiation induction.
[0031] The present invention also provides a use of stem cells treated with one or more compounds selected from the group consisting of a compound of Chemical Formula 1, a compound of Chemical Formula 2, and a compound of Chemical Formula 3 for preventing or treating nerve damage diseases.
[0032] Furthermore, the present invention provides a method for treating a nerve injury disease, comprising the step of transplanting stem cells treated with one or more compounds selected from the group consisting of a compound of Chemical Formula 1, a compound of Chemical Formula 2, and a compound of Chemical Formula 3, into an individual having the nerve injury disease. Effect of the Invention
[0033] According to the present invention, the compound of the present invention can directly induce transdifferentiation of adult stem cells into neural progenitor cells by controlling the oligomerization of CtBPs. The directly transdifferentiated ciNSC5 does not express neural stem cell markers and mature neuron markers, and the expression of intermediate neuronal progenitor or immature neuron marker proteins is significantly increased compared to adult stem cells, and the secretion of secretory proteins including growth factors, tissue degradation factors, ligands involved in neurodifferentiation, neurogenesis and axon regeneration, and cytokines is increased, and the expression of enzymes for neurogenesis, neuroregeneration, neuroprotection, and glial scar decomposition, and neurogenesis-related factors is increased, and the compound of the present invention can be used for inducing oligomerization of CtBPs or direct transdifferentiation induction. The compound of the present invention showed a significant therapeutic effect in both ALS mouse model, MS mouse model, PD Rett model, and chronic spinal cord injury Rett model, so the stem cells treated with the compound of the present invention can be used as a cell therapy agent. [Brief description of the drawings]
[0034] [Figure 1] FIG. 1 shows the results of DARTS (Drug Affinity Responsive Target Stability) analysis of YJ101, YJ102 and YJ103. [Diagram 2] This figure shows the regulatory role of YJ102 in CTBP1 oligomerization, confirmed by immunoprecipitation. [Diagram 3]Molecular docking results of CtBP1 with YJ101, YJ102, and YJ103 are shown. [Figure 4] FIG. 13 shows the target genes of CtBP1-YJ102 confirmed by ChIP method. [Diagram 5] FIG. 1 shows a diagram confirming whether or not YJ102 mediated CtBP1-mediated ciNSC5 differentiation. [Figure 6] FIG. 1 shows a graph confirming the presence or absence of direct trans-differentiation of human UCB-MSCs treated with YJ101, YJ102, or YJ103. [Figure 7] This figure confirms whether mesenchymal stem cells of various origins are directly transdifferentiated by YJ102. [Figure 8] FIG. 1 shows the cytotoxicity of YJ101, YJ102, and YJ103 against UCB-MSCs. [Figure 9] FIG. 1 shows the effects of YJ101, YJ102 and YJ103 on the cell proliferation of UCB-MSCs. [Figure 10] FIG. 13 shows immunofluorescence analysis of the expression of neural markers in ciNSC5 treated with YJ102 for 5 days. [Figure 11] FIG. 13 shows the results of Western blot analysis of the expression of neural progenitor cell marker proteins in ciNSC5 treated with YJ102 for 5 days. [Figure 12] FIG. 13 shows the results of Western blot analysis of MSC cell surface antigen marker protein expression in ciNSC5 treated with YJ102 for 5 days. [Figure 13] FIG. 13 is a graph summarizing the rate of increase / decrease in the results of Western blot analysis in FIGS. 11 and 12. [Figure 14] FIG. 13 shows the growth factors, tissue degradation, and neural differentiation / regeneration-related factors that were increased in ciNSC5 treated with YJ102 for 5 days. [Figure 15] This is a diagram in which the results of Figure 14 are organized by change mode. [Figure 16]ciNSC5 differentiated from UCB-MSCs by YJ102 treatment were passaged and cultured in a YJ102-free medium for 2 days, and the growth factors, tissue degradation, and neural differentiation / regeneration-related proteins in the medium were confirmed by Weston blot analysis. [Figure 17] This is a diagram in which the results of Figure 16 are organized by change mode. [Figure 18] This figure shows the results of Weston blot analysis of ciNSC5 differentiated from UCB-MSCs by YJ102 treatment, after additional culture in a medium without YJ102 for 4 or 7 days, to confirm the levels of growth factors, tissue degradation, and neural differentiation / regeneration-related proteins in the medium. [Figure 19] This is a diagram in which the results of Figure 18 are organized by change mode. [Figure 20] After culturing ciNSC5 in a medium not containing YJ102 for two days, the amounts of growth factors and six tissue degradation-related factors that increased in ciNSC5 in the corresponding medium were measured by ELISA. [Figure 21] FIG. 13 shows the ELISA results and the percentage of increase in ciNSC5 medium compared to the amount observed in MSC medium. [Figure 22] FIG. 1 shows a heat map of the results of RNA-seq analysis of genes expressed in ciNSC5. [Figure 23] Based on the RNA-seq results, genes involved in neurogenesis, synapses, neurotransmitters, nerve growth factors, etc. were selected and analyzed from among the factors whose expression changed in the culture medium on day 5. [Figure 24] FIG. 24 is a table showing the results of the gene ontology analysis of FIG. 23. [Diagram 25] FIG. 13 shows real-time RT-PCR analysis of the expression of enzymes involved in the degradation of glial scars in ciNSC5 differentiated from UCB-MSCs treated with YJ102 for 5 days. [Figure 26] FIG. 13 shows real-time RT-PCR analysis of the expression of transcription factors associated with neurogenesis in ciNSC5 differentiated from UCB-MSCs treated with YJ102 for 5 days. [Figure 27]FIG. 13 shows real-time RT-PCR analysis of the expression of neuronal markers such as myelination, synapsis, matrix / cell attachment, and calcium signaling in ciNSC5 differentiated from UCB-MSCs treated with YJ102 for 5 days. [Figure 28] FIG. 13 shows real-time RT-PCR analysis of the expression of neuronal receptors and channels in ciNSC5 differentiated from UCB-MSCs treated with YJ102 for 5 days. [Figure 29] FIG. 1 shows changes in cell characteristics during subculture of ciNSC5, as confirmed by doubling time at each passage. [Diagram 30] FIG. 13 shows changes in cell properties during subculture of ciNSC5, as confirmed by CPDL values depending on the number of passages. [Diagram 31] FIG. 13 shows Tuj1 expression in ciNSC5 during subculture. [Diagram 32] FIG. 1 shows chromosomal abnormalities confirmed during subculture of ciNSC5 through karyotyping. [Diagram 33] FIG. 1 shows a diagram confirming whether or not ciNSC5 differentiated into neural cells. [Diagram 34] FIG. 1 shows adipogenesis after MDI treatment as confirmed by the expression of its markers, C / EBPα and PPARγ. [Diagram 35] FIG. 1 shows the life span of an ALS mouse model after transplantation of ciNSC5. [Diagram 36] FIG. 1 shows behavioral analysis (rotarod, motor score, hanging wire test, and balance beam test) of an ALS mouse model after ciNSC5 transplantation. [Figure 37] FIG. 13 is a diagram confirming lumbar spinal cord nerve loss in an ALS mouse model after ciNSC5 transplantation. [Figure 38] FIG. 13 shows the behavioral analysis of EAE mouse model after ciNSC5 transplantation. [Figure 39] FIG. 1 shows the extent and degree of demyelination in an EAE mouse model after ciNSC5 transplantation. [Diagram 40]FIG. 13 shows mononuclear cells infiltrated into the white matter periphery of the spinal cord in an EAE mouse model after ciNSC5 transplantation. [Diagram 41] FIG. 13 shows macrophages infiltrated into the spinal cord white matter of an EAE mouse model after ciNSC5 transplantation. [Diagram 42] FIG. 13 shows activation of microglia and astrocytes in the spinal cord of an EAE mouse model after transplantation of ciNSC5. [Diagram 43] FIG. 13 shows activation of microglia and astrocytes in the spinal cord of an EAE mouse model after transplantation of ciNSC5. [Diagram 44] This figure shows the process of creating a PD rat model through 6-OHDA injection and the stereotaxic positions (Partial injury: AP+0.7, ML+2.6, DV-4.5 from bregma; and Complete injury: AP-2.2, ML+1.5, DV-8.0 from bregma). [Diagram 45] FIG. 1 shows the recovery of motor function in a PD-ret model after ciNSC5 transplantation, confirmed by behavioral analysis (rotation test and stepping test). [Figure 46] FIG. 13 shows the loss of dopamine neurons confirmed in the PD-ret model after ciNSC5 transplantation. [Figure 47] This figure shows that engraftment was confirmed using a human-specific antibody (STEM121) in a PD-ret model after ciNSC5 transplantation. [Figure 48] This figure shows that ciNSCs were differentiated into human dopamine neurons after transplantation by confirming the presence of a human-specific antibody (STEM121) and dopamine neurons (TH-positive cells) at the site of cell transplantation into a PD-ret model after ciNSC5 transplantation. [Figure 49] FIG. 1 shows behavioral analysis (BBB, gridwork, and footprint) confirming motor function recovery in a chronic spinal cord injury Rett model after ciNSC5 transplantation. [Figure 50] FIG. 13 shows FRI analysis of motor function recovery in a chronic spinal cord injury Rett model after ciNSC5 transplantation. [Figure 51] FIG. 1 shows lesion volume and myelin loss in a chronic spinal cord injury Rett model after ciNSC5 transplantation. [Figure 52] FIG. 13 shows the extent of gliotic lesion formation at the lesion site in a chronic spinal cord injury Rett model after ciNSC5 transplantation. [Figure 53] FIG. 13 shows axonal regeneration confirmed by BDA-guided axonal tracing in a chronic spinal cord injury Rett model after ciNSC5 transplantation. [Figure 54] FIG. 13 shows axonal regeneration in a chronic spinal cord injury Rett model after ciNSC5 transplantation, confirmed by Fluorogold retrograde axonal tracing. [Figure 55] FIG. 13 shows the expression profile of GAP43, an axon regeneration factor, confirmed by Western blotting in a chronic spinal cord injury Rett model after ciNSC5 transplantation. [Figure 56] This figure shows immunohistochemical staining performed using the human-specific STEM121 antibody and a neuronal marker to confirm whether ciNSC5 cells were differentiated into mature neurons 6 weeks after cell transplantation into a chronic spinal cord injury Rett model. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0035] Hereinafter, the present invention will be described in detail with reference to the accompanying drawings. However, the following embodiments are presented as examples of the present invention, and if it is determined that a detailed description of a technology or configuration well known to those skilled in the art may unnecessarily obscure the gist of the present invention, the detailed description may be omitted and the present invention is not limited thereby. The present invention is subject to various modifications and applications within the scope of the claims described below and the scope of equivalents analyzed therefrom.
[0036] In addition, the terminology used in this specification is used to appropriately express the preferred embodiment of the present invention, and may vary depending on the intention of the user or operator, or the practice of the field to which the present invention belongs. Therefore, the definition of the term must be based on the entire contents of this specification. Throughout the specification, when a part "includes" a certain element, this does not mean that other elements are excluded, but that other elements may be further included, unless otherwise specified.
[0037] All technical terms used in the present invention are used in the sense that they are commonly understood by those of ordinary skill in the art unless otherwise defined. In addition, the present specification describes preferred methods and samples, but similar or equivalent methods and samples are also included in the scope of the present invention. The contents of all publications referenced in this specification are incorporated herein by reference.
[0038] Throughout this specification, "%" used to indicate the concentration of a particular substance is (w / w)% for solid / solid, (w / v)% for solid / liquid, and (v / v)% for liquid / liquid, unless otherwise stated.
[0039] In one aspect, the present invention relates to a benzoxazole derivative represented by the following Chemical Formula 1, a stereoisomer thereof, a pharma- ceutically acceptable salt thereof, or a solvate or hydrate thereof.
[0040] [ka]
[0041] In Chemical Formula 1, R1 to R3 are each independently hydrogen; a halogen group; a C1-C4 linear or branched alkyl group; a C1-C4 linear or branched alkoxy group; a nitro group (-NO2); or an amino group (-NH2); L is a C1-C4 alkylene group; R4 is a C1-C4 straight or branched chain alkoxy group; -C(=O)OR6; or -OC(=O)R7; R5 is hydrogen; a halogen group; a C1-C4 linear or branched alkyl group; or a C1-C4 linear or branched alkoxy group; R6 and R7 are each independently a C1-C4 straight or branched chain alkyl group.
[0042] In the present invention, the term "stereoisomer" refers to an isomer that occurs due to spatial differences in the arrangement of atoms or atomic groups in a molecule, and includes all of enantiomers and geometric isomers.
[0043] In the present invention, the hydrate is a compound in which a benzoxazole derivative, a pharma- ceutically acceptable salt thereof, or a stereoisomer thereof is bound to water by a non-covalent intermolecular force, and may contain a stoichiometric or non-stoichiometric amount of water. Specifically, the hydrate may contain water in a molar ratio of about 0.25 to about 10 moles per mole of active ingredient, more specifically, about 0.5 moles, about 1 mole, about 1.5 moles, about 2 moles, about 2.5 moles, about 3 moles, about 5 moles, etc.
[0044] In the present specification, the term "solvate" refers to a compound in which a benzoxazole derivative, a pharma- ceutical acceptable salt thereof, or a stereoisomer thereof is bound to a solvent other than water by intermolecular forces, and may contain a stoichiometric or non-stoichiometric amount of the solvent. Specifically, the solvate may contain about 0.25 to about 10 moles of the solvent molecules based on 1 mole of the active ingredient, and more specifically, may contain about 0.5 moles, about 1 mole, about 1.5 moles, about 2 moles, about 2.5 moles, about 3 moles, about 5 moles, etc.
[0045] In one embodiment, the benzoxazole derivative represented by Chemical Formula 1 may be a benzoxazole derivative represented by Chemical Formula 2 below, a stereoisomer thereof, a pharma- ceutically acceptable salt thereof, or a solvate or hydrate thereof.
[0046] [ka]
[0047] In Chemical Formula 2, The definitions of L and R1 to R5 are as defined in Chemical formula 1 above. In one embodiment, two of R1 to R3 are hydrogen, and the remaining one may be hydrogen; a halogen group; a C1-C4 linear or branched alkyl group; a C1-C4 linear or branched alkoxy group; a nitro group (-NO2); or an amino group (-NH2).
[0048] In an embodiment of the present invention, the benzoxazole derivative represented by Chemical Formula 1 may be any one of compounds represented by the following Chemical Formula I, Chemical Formula II, or Chemical Formula III.
[0049] [ka]
[0050] In one aspect, the present invention relates to a composition for inducing oligomerization of CtBPs (C-terminal Binding Proteins), comprising at least one selected from the group consisting of a compound of formula I, a compound of formula II, and a compound of formula III.
[0051] In one embodiment, the CtBPs may be CtBP1 or CtBP2.
[0052] In one embodiment, the composition can protect CtBPs from enzymes that induce oligomerization.
[0053] In one embodiment, the oligomerization may be homo-oligomerization of CtBP1-CtBP1 or CtBP2-CtBP2.
[0054] In one embodiment, the compound of formula I, the compound of formula II, and the compound of formula III can bind directly to CtBP1, and the compound of formula 2 can also bind directly to CtBP2.
[0055] In one embodiment, the compound of formula I can bind to Ser100 of CtBP1, the compound of formula II can bind to Ser100 and Arg266 of CtBP1, and the compound of formula III can bind to Phe102, Arg184, and His236 of CtBP1.
[0056] In one embodiment, the composition is capable of reducing the expression of HES1.
[0057] In some embodiments, the composition may increase the expression of Sox2.
[0058] In one embodiment, the composition is capable of inducing expression of OCT4.
[0059] In one embodiment, the composition is capable of CtBPs-mediated differentiation of adult stem cells into neural progenitor cells.
[0060] In one embodiment, the adult stem cells may be mesenchymal stem cells (MSCs), and the mesenchymal stem cells may be umbilical cord blood-derived mesenchymal stem cells (UCB-MSCs), umbilical cord-derived mesenchymal stem cells (UC-MSCs), adipose-derived mesenchymal stem cells (AD-MSCs), or bone marrow-derived mesenchymal stem cells (BM-MSCs).
[0061] In one embodiment, the neural progenitor cells may be chemically induced neural stem cells 5 (ciNSC5).
[0062] In one embodiment, the composition may be a reagent composition or a medium composition. In one aspect, the present invention relates to a composition for inducing direct conversion of adult stem cells into neural progenitor cells, comprising at least one compound selected from the group consisting of a compound of formula I, a compound of formula II, and a compound of formula III.
[0063] In one embodiment, the composition can induce oligomers of CtBPs from adult stem cells to induce CtBPs-mediated direct trans-differentiation into neural progenitor cells.
[0064] In one embodiment, the adult stem cells may be mesenchymal stem cells, and the mesenchymal stem cells may be umbilical cord blood-derived mesenchymal stem cells, adipose-derived mesenchymal stem cells, or bone marrow-derived mesenchymal stem cells, and are not limited thereto, as adult stem cells can be applied regardless of specific tissue cells. In many specific embodiments of the present invention, mesenchymal stem cells derived from umbilical cord (blood) were used, but it was confirmed that direct transdifferentiation into neural progenitor cells is also possible from adipose-derived mesenchymal stem cells and bone marrow-derived mesenchymal stem cells.
[0065] In one embodiment, the neural progenitor cells may be ciNSC5.
[0066] In one embodiment, the composition may increase expression of a neural marker, and the neural marker may be Tuj1, TBR2, MASH1, GAP-43, or p75.
[0067] In one embodiment, the composition can increase the expression of a neural progenitor cell marker protein, which may be Tuj1 protein, CD325 (N-cadherin) protein, p75 protein, GAP-43 protein, CD54 protein, CD309 protein, CD56 (NCAM) protein, PSA-NCAM protein, CD29 protein, MASH1 protein, or TBR2 protein, and can increase Tuj1 protein by 6-fold or more, preferably 6-8-fold, and CD325 (N-cadherin) protein by 7-fold after induction compared to before induction of direct transdifferentiation. or more, preferably 7 to 10 times, p75 protein 4 times or more, preferably 4 to 8 times, GAP43 protein 4 times or more, preferably 4 to 7 times, CD54 protein 2 times or more, preferably 2 to 5 times, CD309 protein 3 times or more, preferably 3 to 7 times, CD56 (NCAM) protein 3.5 times or more, preferably 3.5 to 6 times, PSA-NCAM protein 4 times or more, preferably 4 to 6 times, CD29 protein 4.5 times or more, preferably 4.5 to 8 times, MASH1 protein 4 times or more, preferably 4 to 8 times, or TBR2 protein 3 times or more, preferably 3 to 7 times.
[0068] In one embodiment, the composition can reduce the expression of an adult stem cell marker protein, which may be CD44, CD73 or CD105, and can reduce the expression of CD44 protein by 50-90%, CD73 protein by 30-70%, or CD105 protein by 50-90% after direct transdifferentiation induction compared to before induction.
[0069] In one embodiment, the composition may increase secretion of a secreted protein, which may be a growth factor, tissue degradation factor, ligand, or cytokine.
[0070] In one embodiment, the growth factor may be PlGF, NGF, BDNF or VEGFA, and the secretion of PlGF can be increased by 1.5 to 4 times, NGF by 1.5 to 6 times, BDNF by 1.5 to 3 times, or VEGFA by 1.5 to 5 times after direct transdifferentiation induction compared to before induction.
[0071] In one embodiment, the tissue degradation factor may be MMP1, MMP2, MMP7 or TIMP2, and may increase the secretion of MMP1 by 1.5 to 3.5 times or MMP2 by 2 to 6 times after direct transdifferentiation induction compared to before induction.
[0072] In one embodiment, the ligand may be SHH or Notch1.
[0073] In one embodiment, the cytokine may be TNFSF12 or IL-16, and the secretion of TNFSF12 may be increased by 1.5 to 4 times after induction of direct transdifferentiation compared to before induction.
[0074] In one embodiment, the composition may be a reagent composition or a media composition.
[0075] In the present invention, the expression level of the mRNA of the marker gene can be measured by polymerase chain reaction, real-time RT-PCR, reverse transcription polymerase chain reaction, competitive RT-PCR, nuclease protection assay (RNase, S1 nuclease assay), in situ hybridization, nucleic acid microarray, Northern blot, or DNA chip method using a nucleic acid sequence of the marker, a nucleic acid sequence complementary to the nucleic acid sequence, or a primer pair, probe, or a primer pair and probe that specifically recognize a fragment of the nucleic acid sequence and the complementary sequence, and the protein expression level of the marker can be measured by Western blot, enzyme linked immunosorbent assay (ELISA) using an antibody, antibody fragment, aptamer, avidity multimer, or peptidomimetics that specifically recognizes the full length protein or a fragment thereof of the marker. The activity can be measured by immunohistochemistry, immunoassay (RIA), radioimmunoassay (RIA), radioimmunodiffusion, immunoelectrophoresis, tissue immunostaining, immunoprecipitation assay, complement fixation assay, FACS, mass spectrometry, or protein microarray methods.
[0076] The term "direct reprogramming, direct conversion, transdifferentiation" used in the present invention refers to a technology that induces conversion between mature (differentiated) cells with completely different cell types in higher organisms by "directly" converting any somatic cell (cell type A) into a desired specific cell (cell type B) without going through the process of redifferentiation (re-differentiation) after reverse differentiation into induced pluripotent stem cells that can differentiate into all cells. Currently, direct transdifferentiation is recognized as having the potential to be used in disease modeling and new drug discovery, and is expected to be applied to gene therapy and regenerative medicine in the future.
[0077] In one aspect, the present invention relates to a method for inducing oligomerization of CtBPs in vitro, comprising treating a sample with any one or more selected from the group consisting of a compound of formula I, a compound of formula II, and a compound of formula III.
[0078] In one embodiment, the compound may be treated for 3 to 7 days, and most preferably for 5 days.
[0079] In one embodiment, the CtBPs may be CtBP1 or CtBP2.
[0080] In one embodiment, the oligomerization may be homo-oligomerization of CtBP1-CtBP1 or CtBP2-CtBP2.
[0081] In one embodiment, the sample may be an adult stem cell, and in one embodiment, the adult stem cell may be a mesenchymal stem cell, and the mesenchymal stem cell may be an umbilical cord blood-derived mesenchymal stem cell (UCB-MSC), an umbilical cord-derived mesenchymal stem cell, an adipose-derived mesenchymal stem cell, or a bone marrow-derived mesenchymal stem cell.
[0082] In one embodiment, the method can increase Tuj1, CD325 (N-cadherin), p75, GAP-43, CD309, CD56 (NCAM), PSA-NCAM, CD29, MASH1 or TBR2 expression in a sample after treatment with a compound compared to before treatment, and can increase Tuj1 by 6-fold or more, preferably 6-8-fold, CD325 (N-cadherin) by 7-fold or more, preferably 7-10-fold, p75 by 4-fold or more, preferably 4-8-fold, The expression of GAP43 can be increased by 4 times or more, preferably 4 to 7 times, CD54 by 2 times or more, preferably 2 to 5 times, CD309 by 3 times or more, preferably 3 to 7 times, CD56 (NCAM) by 3.5 times or more, preferably 3.5 to 6 times, PSA-NCAM by 4 times or more, preferably 4 to 6 times, CD29 by 4.5 times or more, preferably 4.5 to 8 times, MASH1 by 4 times or more, preferably 4 to 8 times, or TBR2 by 3 times or more, preferably 3 to 7 times.
[0083] In an embodiment, the method can increase secretion of growth factors, tissue degradation factors, ligands, or cytokines in the sample after treatment with the compound compared to before treatment; increase secretion of PlGF, NGF, BDNF, VEGFA, MMP1, MMP2, MMP7, TIMP2, SHH, Notch1, TNFSF12, or IL-16 in the sample after treatment with the compound compared to before treatment with the compound, increasing secretion of PlGF by 1.5 to 4 times, NGF by 1.5 to 6 times, BDNF by 1.5 to 3 times, VEGFA by 1.5 to 5 times, MMP1 by 1.5 to 3.5 times, MMP2 by 2 to 6 times, or TNFSF12 by 1.5 to 4 times; and decrease expression of CD44, CD73, or CD105 in the sample after treatment with the compound compared to before treatment with the compound, decreasing expression of CD44 by 50 to 90%, CD73 by 30 to 70%, or CD105 by 50 to 90%.
[0084] In one aspect, the present invention relates to a method for inducing direct trans-differentiation of adult stem cells into neural progenitor cells, comprising the step of treating adult stem cells in vitro with any one or more compounds selected from the group consisting of a compound of formula I, a compound of formula II, and a compound of formula III.
[0085] In one embodiment, the compound may be treated for 3 to 7 days, and most preferably for 5 days.
[0086] In one embodiment, direct transdifferentiation may be induced via CtBPs-mediated, more preferably via oligomerization of CtBPs.
[0087] In one embodiment, the method can increase the expression of Tuj1, CD325 (N-cadherin), p75, GAP-43, CD309, CD56 (NCAM), PSA-NCAM, CD29, MASH1 or TBR2 in cells after compound treatment compared to before treatment, and can increase the expression of Tuj1 by 2-5 fold, CD325 (N-cadherin) by 3-6 fold, p75 by 1.5-4 fold, GAP43 by 2-6 fold, CD309 by 1.5-3 fold, CD56 (NCAM) by 1.5-4.5 fold, PSA-NCAM by 1.5-4 fold, CD29 by 1.5-4 fold, MASH by 2-4 fold or TBR2 by 5-9 fold.
[0088] In some embodiments, the method may increase secretion of a growth factor, tissue degradation factor, ligand, or cytokine by the cells after treatment with the compound compared to before treatment.
[0089] In one embodiment, the method can increase secretion of PlGF, NGF, BDNF, VEGFA, MMP1, MMP2, MMP7, TIMP2, SHH, Notch1, TNFSF12 or IL-16 by cells after treatment with a compound compared to before treatment, resulting in an increase in secretion of 1.5 to 4 times more PlGF, 1.5 to 6 times more NGF, 1.5 to 3 times more BDNF, 1.5 to 5 times more VEGFA, 1.5 to 3.5 times more MMP1, 2 to 6 times more MMP2, or 1.5 to 4 times more TNFSF12.
[0090] In one embodiment, the method may reduce expression of CD44, CD73 or CD105 in cells after treatment with the compound compared to before treatment, and may reduce CD44 expression by 50-90%, CD73 expression by 30-70%, or CD105 expression by 40-80%.
[0091] The direct trans-differentiation induced by the composition for inducing direct trans-differentiation and the direct trans-differentiation method of the present invention can induce direct differentiation from adult stem cells into neural progenitor cells, which can be further differentiated into neural cells and / or dopamine neural cells. In this case, the direct trans-differentiation method can further include a step of differentiating neural progenitor cells obtained by introducing any one or more selected from the group consisting of the compound of formula I, the compound of formula II, and the compound of formula III of the present invention, into adult stem cells, into neural cells or dopamine neural cells, and the step of differentiating mesenchymal stem cells into neural cells or dopamine neural cells can be performed by applying a general differentiation technique.
[0092] In one aspect, the present invention relates to stem cells treated with any one or more compounds selected from the group consisting of a compound of formula I, a compound of formula II, and a compound of formula III.
[0093] In one embodiment, the stem cells treated with the compound may be adult stem cells, and the adult stem cells may be mesenchymal stem cells (MSCs), and the mesenchymal stem cells may be umbilical cord blood-derived mesenchymal stem cells (UCB-MSCs), umbilical cord-derived mesenchymal stem cells (UC-MSCs), adipose-derived mesenchymal stem cells (AD-MSCs), or bone marrow-derived mesenchymal stem cells (BM-MSCs).
[0094] In one embodiment, the stem cells of the present invention may be stem cells treated in vitro with any one or more compounds selected from the group consisting of a compound of formula I, a compound of formula II, and a compound of formula III for 3 to 7 days, or may be stem cells produced by a method including the steps of: treating stem cells with any one or more compounds selected from the group consisting of a compound of formula I, a compound of formula II, and a compound of formula III; and culturing the compound-treated stem cells for 3 to 7 days.
[0095] In one embodiment, the stem cells of the present invention may be stem cells treated with the compound dissolved in DMSO at 30 mM and at a concentration of 5 to 100 uM.
[0096] In one embodiment, the stem cells of the present invention may be neural progenitor cells that have been directly converted into adult stem cells by treatment with a compound, and the neural progenitor cells may be ciNSC5 (chemically induced neural stem cell 5).
[0097] In one embodiment, the stem cells of the present invention may have increased expression of neural markers compared to stem cells not treated with the compound, and the neural markers may be Tuj1, TBR2, MASH1, GAP-43 or p75.
[0098] In one embodiment, the stem cells of the present invention may have increased expression of neural progenitor cell marker proteins compared to stem cells not treated with the compound, and the neural progenitor cell marker proteins may be Tuj1 protein, CD325 (N-cadherin) protein, p75 protein, GAP-43 protein, CD54 protein, CD309 protein, CD56 (NCAM) protein, PSA-NCAM protein, CD29 protein, MASH1 protein, or TBR2 protein.
[0099] In one embodiment, the stem cells of the present invention may have an increased expression of Tuj1 protein of 6 times or more, preferably 6 to 8 times, CD325 (N-cadherin) protein of 7 times or more, preferably 7 to 10 times, p75 protein of 4 times or more, preferably 4 to 8 times, GAP43 protein of 4 times or more, preferably 4 to 7 times, CD54 protein of 2 times or more, preferably 2 to 5 times, CD309 protein of 3 times or more, preferably 3 to 7 times, CD56 (NCAM) protein of 3.5 times or more, preferably 3.5 to 6 times, PSA-NCAM protein of 4 times or more, preferably 4 to 6 times, CD29 protein of 4.5 times or more, preferably 4.5 to 8 times, MASH1 protein of 4 times or more, preferably 4 to 8 times, or TBR2 protein of 3 times or more, preferably 3 to 7 times, compared to stem cells not treated with the compound.
[0100] In one embodiment, the stem cells of the present invention may have reduced expression of CD44, CD73 or CD105 compared to stem cells not treated with the compound, and CD44 protein expression may be reduced by 50-90%, CD73 protein expression may be reduced by 30-70%, or CD105 protein expression may be reduced by 50-90%.
[0101] In one embodiment, the stem cells of the present invention may have increased secretion of a secretory protein compared to stem cells not treated with the compound, and the secretory protein may be a growth factor, tissue degradation factor, ligand, or cytokine.
[0102] In one embodiment, the growth factor may be PlGF, NGF, BDNF or VEGFA, and the stem cells of the present invention may have 1.5 to 4 times increased PlGF secretion, 1.5 to 6 times increased NGF secretion, 1.5 to 3 times increased BDNF secretion, or 1.5 to 5 times increased VEGFA secretion, compared to stem cells not treated with the compound.
[0103] In one embodiment, the tissue degradation factor may be MMP1, MMP2, MMP7 or TIMP2, and the stem cells of the present invention may have a 1.5 to 3.5 fold increase in MMP1 secretion or a 2 to 6 fold increase in MMP2 secretion compared to stem cells not treated with the compound.
[0104] In one embodiment, the ligand may be SHH or Notch1.
[0105] In one embodiment, the cytokine may be TNFSF12 or IL-16, and the stem cells of the present invention may secrete 1.5 to 4 times more TNFSF12 than stem cells not treated with the compound.
[0106] In one embodiment, the stem cells of the present invention may have increased expression of HES1, Sox2 or OCT4 compared to stem cells not treated with the compound.
[0107] In one embodiment, the stem cells of the present invention can be treated with a compound to induce oligomerization of CtBPs (C-terminal Binding Proteins), and the compound can induce oligomerization by protecting CtBPs from enzymes.
[0108] In one embodiment, the CtBPs may be CtBP1 or CtBP2.
[0109] In one embodiment, the oligomerization may be homo-oligomerization of CtBP1-CtBP1 or CtBP2-CtBP2.
[0110] In one embodiment, the compound of formula I, the compound of formula II, and the compound of formula III can bind directly to CtBP1, and the compound of formula II can also bind directly to CtBP2.
[0111] In one embodiment, the compound of formula I can bind to Ser100 of CtBP1, the compound of formula II can bind to Ser100 and Arg266 of CtBP1, and the compound of formula III can bind to Phe102, Arg184, and His236 of CtBP1.
[0112] In one embodiment, the compound can mediate CtBPs-mediated differentiation of adult stem cells into neural progenitor cells.
[0113] In one embodiment, the compound can induce oligomers of CtBPs from adult stem cells to induce CtBPs-mediated direct trans-differentiation into neural progenitor cells.
[0114] In one embodiment, the adult stem cells may be mesenchymal stem cells, which may be umbilical cord blood-derived mesenchymal stem cells (UCB-MSC), umbilical cord-derived mesenchymal stem cells, adipose-derived mesenchymal stem cells, or bone marrow-derived mesenchymal stem cells, and are not limited thereto, as adult stem cells can be applied regardless of specific tissue cells. In many specific embodiments of the present invention, mesenchymal stem cells derived from umbilical cord (blood) were used, but it was confirmed that direct transdifferentiation into neural progenitor cells is also possible from adipose-derived mesenchymal stem cells and bone marrow-derived mesenchymal stem cells.
[0115] In one embodiment, the stem cells of the present invention may not express MAP2, NSE, NeuN, doublecortin, NeuroD1 (Neurogenic differentiation 1), Nestin, Mussashi 1, or GFAP.
[0116] In one embodiment, the stem cells of the present invention may have increased expression of neurogenesis-inducing genes, inducible neurotrophic factor secretion genes, neurogenesis-related genes, neuronal marker genes, neuronal receptor genes, and channel-related genes compared to stem cells not treated with the compound.
[0117] In some embodiments, the stem cells of the present invention may have increased expression of enzymes for degrading glial scars compared to stem cells not treated with the compound.
[0118] In one embodiment, the stem cells of the present invention can differentiate into dopaminergic neurons, neuronal cells or mature neuronal cells.
[0119] In one embodiment, the stem cells of the present invention may not be induced to undergo adipogenesis.
[0120] The term "expression" as used herein refers to the process by which a nucleic acid is transcribed from a DNA template (e.g., into mRNA or other RNA transcripts) and / or the subsequent translation of the transcribed mRNA into a peptide, polypeptide, or protein.
[0121] In the present invention, the expression level of the mRNA of the gene can be measured by polymerase chain reaction, real-time RT-PCR, reverse transcription polymerase chain reaction, competitive RT-PCR, nuclease protection assay (RNase, S1 nuclease assay), in situ hybridization, nucleic acid microarray, Northern blot, or DNA chip method using a nucleic acid sequence of the marker, a nucleic acid sequence complementary to the nucleic acid sequence, or a primer pair, probe, or a primer pair and probe that specifically recognize a fragment of the nucleic acid sequence and the complementary sequence, and the expression level of the protein of the gene can be measured by Western blot, enzyme linked immunosorbent assay (ELISA) using an antibody, antibody fragment, aptamer, avidity multimer, or peptidomimetics that specifically recognizes the full length of the corresponding protein or a fragment thereof. The activity can be measured by immunohistochemistry, immunoassay (RIA), radioimmunoassay (RIA), radioimmunodiffusion, immunoelectrophoresis, tissue immunostaining, immunoprecipitation assay, complement fixation assay, FACS, mass spectrometry, or protein microarray methods.
[0122] The term "direct reprogramming, direct conversion, transdifferentiation" as used in the present invention refers to a technology that induces conversion between mature (completely differentiated) cells with completely different cell types in higher organisms, in which any somatic cell (cell type A) is reverse-differentiated into an induced pluripotent stem cell capable of differentiating into any cell type, and then "directly" converted into a desired specific cell (cell type B) without going through the process of re-differentiation.
[0123] The stem cells treated with the compound of the present invention can be directly transdifferentiated into neural progenitor cells, which can then be further differentiated into mature neural cells and / or dopamine neural cells. In this case, the present invention can further include a configuration for differentiating the stem cells treated with the compound into neural cells or dopamine neural cells, and the step of differentiating the mesenchymal stem cells into neural cells or dopamine neural cells can be carried out by applying a general differentiation technique.
[0124] In one aspect, the present invention relates to a pharmaceutical composition for preventing or treating a nerve damage disease, comprising the stem cell, stem cell culture, or suspension culture of the present invention as an active ingredient.
[0125] In one embodiment, the nerve damage disease may be a central or peripheral nervous system injury or a neurodegenerative disease, and may be a CNS (central nervous system) injury disease.
[0126] In one embodiment, the injury to the central or peripheral nervous system may be a spinal cord injury (SCI), a traumatic brain injury (TBI), a peripheral nerve injury, a stroke, or brain cancer.
[0127] In one embodiment, the spinal cord injury may be induced by trauma or inflammation, and may be induced by one or more of the following: acute transverse myelitis, acute disseminated myelitis, myelopathy, non-Hodgkin's lymphoma, hydrocephalus, hereditary ataxia, neurosyphilis, Minamata disease, Lou Gehrig's disease, and multiple sclerosis.
[0128] In one embodiment, the neurodegenerative disease may be Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), multiple sclerosis (MS) or multiple system atrophy, and more preferably Parkinson's disease, amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS).
[0129] In one embodiment, the composition of the present invention can significantly inhibit the death of motor neurons in the spinal cord, delay the progression of Lou Gehrig's disease symptoms accompanied by motor function disorders, and extend lifespan, thereby achieving the preventive or therapeutic effect of Lou Gehrig's disease.
[0130] In one embodiment, the composition of the present invention can achieve the preventive or therapeutic effect of multiple sclerosis (MS) by inhibiting demyelination of the CNS, inhibiting infiltration of monocytes or macrophages into the spinal cord white matter, and inhibiting activation of microglia or astrocytes.
[0131] In one embodiment, the composition of the present invention can suppress the loss of dopamine neurons and differentiate the transplanted stem cells of the present invention into dopamine neurons, thereby achieving the preventive or therapeutic effect of Parkinson's disease (PD).
[0132] In one embodiment, the composition of the present invention can achieve the preventive or therapeutic effect of chronic spinal cord injury by reducing myelin loss, reducing gliotic scar formation, increasing axons, and differentiating transplanted stem cells of the present invention into mature neurons.
[0133] The term "prevention" as used in the present invention means any action of suppressing or delaying the occurrence, development and recurrence of a nerve damage disease by administering the composition according to the present invention.
[0134] The term "treatment" as used in the present invention means any action of improving or favorably modifying the symptoms of nerve damage disease and complications caused by the administration of the composition according to the present invention. Those skilled in the art to which the present invention pertains should be able to refer to materials presented by the Korean Medical Association and the like to know the exact criteria for diseases for which the composition of the present application is effective, and to judge the degree of improvement, enhancement, and treatment.
[0135] The term "treatment" as used herein refers to an approach to obtain beneficial or favorable clinical results. For purposes of this invention, beneficial or favorable clinical results include, but are not limited to, alleviation of symptoms, reduction in the extent of disease, stabilization of the disease state (i.e., not worsening), slowing or reducing the rate of disease progression, improvement or palliation and relief (partial or total) of the disease state, whether detectable or undetectable.
[0136] "Treatment" can also mean prolonging survival as compared to expected survival if not receiving treatment. "Treatment" refers to all therapeutic treatments and prophylactic or preventative methods of care. Said treatment includes treatment required for disorders already in progress as well as disorders that are prevented. "Palliating" a disease means a reduction in the extent and / or unfavorable clinical signs of the disease state and / or a slowing or prolonging of the time course of progression as compared to the absence of treatment.
[0137] The therapeutically effective amount of the composition of the present invention may vary depending on various factors, such as the method of administration, the target site, and the condition of the individual.
[0138] The pharmaceutical composition of the present invention is administered in a pharmacologic effective amount. The term "pharmacologic effective amount" used in the present invention means an amount sufficient to treat a disease with a reasonable benefit / risk ratio applicable to medical treatment and without causing side effects, and the effective dose level can be determined by factors including the individual's health condition, the type and severity of the neurological damage disease, the activity of the drug, sensitivity to the drug, the administration method, administration time, administration route and excretion rate, treatment period, combined or co-used drugs, and other factors well known in the medical field. The composition of the present invention can be administered as an individual therapeutic agent or in combination with other therapeutic agents, and can be administered sequentially or simultaneously with conventional therapeutic agents, and can be administered singly or multiple times. Taking into account all of the above factors, it is important to administer an amount that can obtain the maximum effect at the minimum amount without side effects, which can be easily determined by those skilled in the art.
[0139] The term treatment, unless otherwise specified, means reversing, alleviating, inhibiting the progression of, or preventing the disease or disorder to which the term applies, or one or more symptoms of the disease or disorder, and the term treatment as used herein refers to the act of treating, as "treating" is defined above. Thus, treatment or therapeutic therapy of an autoimmune disease in a mammal can include one or more of the following: (1) Inhibit the growth of nerve damage diseases, i.e., stop their development; (2) Prevent the spread of neurodegenerative diseases, i.e., prevent metastasis; (3) Reduces nerve damage diseases. (4) Preventing recurrence of neurological disorders; and (5) Palliating the symptoms of nerve damage diseases.
[0140] A composition is "pharmacologically or physiologically acceptable" if the recipient animal can tolerate administration of the composition or if administration of the composition to the animal is suitable. The formulation is said to be administered in a "therapeutically effective amount" if the amount administered is physiologically significant. The formulation is physiologically significant if its presence results in a detectable change in the physiology of the recipient patient.
[0141] As used herein, an "effective amount" is an amount adequate to affect beneficial or favorable clinical or biochemical outcomes. An effective amount can be administered one or more times. For purposes of this invention, an effective amount of a facilitating agent is an amount adequate to temporarily palliate, ameliorate, stabilize, reverse, slow or retard the progression of the associated disease state.
[0142] The therapeutically effective amount of the composition of the present invention may vary depending on many factors, such as the administration method, the target site, and the condition of the patient. Therefore, the dosage for use in the human body must be determined appropriately, taking into consideration both safety and efficacy. It is also possible to estimate the amount to be used in humans from the effective amount determined through animal experiments. Such matters to be considered when determining the effective amount are described, for example, in Hardman and Limbird, eds., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th ed. (2001), Pergamon Press; and EW Martin ed., Remington's Pharmaceutical Sciences, 18th ed. (1990), Mack Publishing Co.
[0143] The pharmaceutical composition of the present invention is administered in a pharmacologic effective amount. The term "pharmacologic effective amount" used in the present invention means an amount sufficient to treat a disease with a reasonable benefit / risk ratio applicable to medical treatment and without causing side effects, and the effective dose level can be determined by factors including the patient's health condition, type and severity of the disease, drug activity, drug sensitivity, administration method, administration time, administration route and excretion rate, treatment period, co-administered or co-used drugs, and other factors well known in the medical field. The composition of the present invention can be administered as an individual therapeutic agent or in combination with other therapeutic agents, and can be administered sequentially or simultaneously with conventional therapeutic agents, and can be administered singly or multiple times. Taking all of the above factors into consideration, it is important to administer an amount that can obtain the maximum effect at the minimum amount without side effects, which can be easily determined by those skilled in the art.
[0144] The pharmaceutical composition of the present invention may contain carriers, diluents, excipients, or combinations of two or more thereof that are commonly used in biological preparations. The term "pharmaceutical acceptable" as used in the present invention means that the composition exhibits the property of being non-toxic to cells or humans exposed to the composition. The carrier is not particularly limited as long as it is suitable for in vivo delivery of the composition, and may be, for example, a compound listed in the Merck Index, 13th ed., Merck & Co. Inc., saline, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol, or a mixture of one or more of these components, and other common additives such as antioxidants, buffers, bacteriostatic agents, etc. may be added as necessary. In addition, the composition may be formulated in the main dosage forms such as aqueous solutions, suspensions, emulsions, etc., pills, capsules, granules, or refined by additionally adding diluents, dispersants, surfactants, binders, and lubricants. Furthermore, the composition can be formulated preferably according to each disease or each component using a suitable method in the art or the method disclosed in Remington's Pharmaceutical Sciences (Mack Publishing Company, Easton PA, 18th, 1990).
[0145] In one embodiment, the pharmaceutical composition may be in one or more dosage forms selected from the group including oral dosage forms, topical preparations, suppositories, sterile injection solutions, and sprays.
[0146] The composition of the present invention may also contain carriers, diluents, excipients, or combinations of two or more of these that are commonly used in biological preparations. The pharma-ceutically acceptable carrier is not particularly limited as long as it is suitable for in vivo delivery of the composition, and may be, for example, a compound described in the Merck Index, 13th ed., Merck & Co. Inc., saline, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol, or a mixture of one or more of these components, and other common additives such as antioxidants, buffers, bacteriostatic agents, etc., may be added as necessary. In addition, the composition may be formulated into a main application form such as an aqueous solution, suspension, emulsion, pill, capsule, granule, or refined form by additionally adding a diluent, dispersant, surfactant, binder, and lubricant. Furthermore, the composition may be formulated according to each disease or according to each component by using a proper method in the art or a method disclosed in Remington's Pharmaceutical Science (Mack Publishing Company, Easton PA, 18th, 1990).
[0147] The composition of the present invention may further comprise one or more active ingredients exhibiting the same or similar functions.
[0148] The pharmaceutical composition of the present invention may further contain a pharma- ceutically acceptable additive, and examples of the pharma-ceutically acceptable additive include starch, gelatinized starch, amorphous cellulose, lactose, povidone, colloidal silicon dioxide, calcium hydrogen phosphate, lactose, mannitol, candy, gum arabic, pregelatinized starch, corn starch, powdered cellulose, hydroxypropyl cellulose, Opadry, sodium starch glycolate, carnauba wax, synthetic aluminum silicate, stearic acid, magnesium stearate, aluminum stearate, calcium stearate, sucrose, dextrose, sorbitol, and talc. The pharma-ceutically acceptable additive according to the present invention is preferably contained in an amount of 0.1 to 90 parts by weight based on the composition, but is not limited thereto.
[0149] The composition of the present invention can be administered parenterally (e.g., intravenously, subcutaneously, intraperitoneally or topically) or orally depending on the intended method, and the dosage range varies depending on the patient's weight, age, sex, health condition, diet, administration time, administration method, excretion rate, severity of disease, etc. The daily dosage of the composition of the present invention is 0.0001 to 10 mg / ml, preferably 0.0001 to 5 mg / ml, and more preferably administered once or in divided doses per day.
[0150] Liquid preparations for oral administration of the composition of the present invention include suspensions, liquid preparations for internal use, emulsions, syrups, etc., which may contain various excipients such as wetting agents, sweeteners, flavoring agents, preservatives, etc. in addition to water and liquid paraffin, which are commonly used simple diluents. Preparations for parenteral administration include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried preparations, suppositories, etc.
[0151] In one aspect, the present invention relates to the use of a compound of formula I, a compound of formula II or a compound of formula III for use in inducing oligomerization of CtBPs.
[0152] In one aspect, the present invention relates to the use of a compound of formula I, a compound of formula II or a compound of formula III for use in direct transdifferentiation induction.
[0153] In one aspect, the present invention relates to a use of stem cells treated with any one or more compounds selected from the group consisting of a compound of formula I, a compound of formula II, and a compound of formula III for the prevention or treatment of nerve damage diseases.
[0154] In one aspect, the present invention relates to a method for treating a nerve injury disease, comprising transplanting stem cells treated with any one or more compounds selected from the group consisting of a compound of formula I, a compound of formula II, and a compound of formula III into an individual having the nerve injury disease.
[0155] The present invention will be described in more detail with reference to the following examples, which are merely intended to illustrate the present invention and are not intended to limit the present invention. EXAMPLES
[0156] Example 1. Modulation of CTBP1 oligomerization by compounds of the present invention 1-1. Identification of YJ101, YJ102, and YJ103-binding proteins through DART analysis DART analysis was performed to identify proteins that bind to the compounds of the present invention, YJ101 (Formula I), YJ102 (Formula II) and YJ103 (Formula III), in human UCB-MSCs (umbilical cord blood-derived mesenchymal stem cells). Specifically, UCB-MSCs (Kang Stem Cell, Passage #6) were distributed into 100 mM culture dishes and cultured in KSB-3 medium (Cat. K3901, Kang Stem Cell) containing 10% FBS (Cat. 16000044), then harvested and washed with PBS. Then, the cells were sonicated in IP50 lysis buffer [50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 2 mM MgCl2 and 0.1% NP40] and centrifuged at 13,000 x g for 10 minutes at 4 °C to obtain the supernatant. The supernatant was added with 1 / 10 volume of 10X TNC buffer [500mM Tris-HCl (pH 8.0), 500mM NaCl and 100mM CaCl2], and the protein concentration was measured by the Bradford method. Next, 9μl of cell lysate and 1μl of YJ101 (20 or 40μM), YJ102 (20 or 30μM) or YJ103 (20 or 40μM) were mixed in a microcentrifuge tube and incubated at room temperature for 1 hour. The control group was treated with 1μl of DMSO. After the incubation, 1μl (1mg / ml) of Pronase (Cat.10 165 921 001, Roche) diluted to 1mg / ml with 1X TNC buffer was added to the microcentrifuge tube and incubated at 37℃ for 15 minutes. After incubation, 1 / 5 volume of 5X SDS-PAGE loading buffer was added, and the mixture was heated at 100°C for 5 minutes, after which SDS-PAGE and coomassie blue staining were performed. UCB-MSCs were also plated in a 60 mm culture dish at 4 × 10 5After 24 hours, 4 μg of FLAG-CtBP1 or FLAG-CtBP2 DNA was transfected using 4 μl of jetPRIME. After 48 hours, cells were harvested and protein was extracted and quantified in the same manner as above. DARTS analysis was performed with cell lysates and Y102 for FLAG-tagged CtBP1, and Western blot analysis was performed with flag antibody (Cat.F3165, Sigma).
[0157] As a result, after DARTS analysis, the band (*) protected by YJ102 was confirmed and identified as CtBP1 (C-terminal Binding Proteins) (Figure 1A). It was shown that YJ102 protects CtBP1 from being degraded by pronase (Figure 1B), overexpressed CtBP1 is protected by YJ102 from being degraded by pronase (Figure 1C), and overexpressed CtBP1 (flag-CtBP1) is protected by YJ101, YJ102 and YJ103 from being degraded by pronase (Figure 1D). It was also shown that YJ102 protects CtBP2 from being degraded by pronase (Figure 1E), and it was confirmed that overexpressed CtBP2 is also protected by YJ102 from being degraded by pronase (Figure 1F).
[0158] Through this, we confirmed that YJ101, YJ102, and YJ103 all bind to CtBP1, and that YJ102 binds to CtBP1 and CtBP2 in human UCB-MSCs.
[0159] 1-2. Confirmation of regulation of CTBP1 oligomerization by YJ102 To confirm the effect of YJ102 on regulating the oligomerization of CtBPs (C-terminal binding proteins) in human UCB-MSCs, we performed immunoprecipitation analysis. Specifically, UCB-MSCs were cultured in a 60 mM culture dish at 4 × 10 5The next day, FLAG-CtBP1, HA-CtBP1, FLAG-CtBP2 and HA-CtBP1 were transfected into the cells using 4μl jetPRIME. Then, YJ102 (stock 30mM in DMSO) and MTOB (stock 300mM in DMSO) were treated with 20uM and 300uM, respectively (Table 1). 48 hours after transfection, proteins were extracted in the same manner as in Example 1-1. Protein G agarose slurry was washed with PBS, blocked with 1ml of 1% BSA, washed with PBS, and 1μg of anti-HA antibody diluted with 1.5ml of PBS was added and incubated at 4℃ for 2 hours. Then, the cells were centrifuged at 3,000×g for 2 minutes, the supernatant was removed, washed twice with IP150 buffer, and 1 μg of the extracted protein was added and incubated at 4°C overnight. After incubation, the cells were centrifuged at 3,000×g for 2 minutes, the supernatant was removed, washed three times with PBS, and 50 μl of 1 mg / ml HA peptide diluted with PBS was added and incubated at room temperature for 10 minutes. After centrifugation at 3,000×g for 2 minutes, the supernatant was transferred to a new microcentrifuge tube, 10 μl of 5X sample buffer was added, and the cells were heated at 100°C for 5 minutes to perform Western blot analysis with FLAG antibody or HA antibody.
[0160] [Table 1]
[0161] As a result, it was shown that YJ102 induces oligomerization of CtBP1, and that such oligomerization is inhibited by MTOB (Figure 2). On the other hand, it was shown that YJ102 has no effect on CtBP1-CtBP2 heteromerization. MTOB is a substrate of the dehydrogenase possessed by CtBP, and is known to act as an inhibitor that suppresses the transcriptional activity of CtBP at high concentrations, thereby suppressing oligomerization.
[0162] 1-3. Confirmation of the interaction sites of YJ101, YJ102, and YJ103 with CtBP1 Molecular docking was performed to confirm the site where the compounds YJ101, YJ102 and YJ103 of the present invention interact with CtBP1. Specifically, protein-ligand docking was performed using Glide (Grid based LIgand Docking with Energetics) docking application of the Schrodinger uites program Schrodinger LC, Y, SA), and the three-dimensional structures of CtBP1 protein (PDB ID: 6CDF) and YJ102 were generated using Schrodinger sites. In addition, a receptor grid for CtBP1 was generated by identifying the binding (active) site residues and confirmed by SiteMap. After generating the receptor grid, the ligand was docked to CtBP1 using the Glide docking protocol, and the docked conformer was evaluated using Glide (G)Score. G Score was calculated using the following formula 1.
[0163]
number
[0164] As a result, it was shown that YJ101, YJ102 and YJ103 all interact with the NAD(H)-binding domain of CtBP1, with ΔG values of -4.980 kcal / mol for YJ101, -5.458 kcal / mol for YJ102 and -3.767 kcal / mol for YJ103 (Fig. 3A). It was also predicted that Ser100 of CTBP1 is important for the interaction between YJ101 and CTBP1, Ser100 and Arg266 of CTBP1 are important for the interaction between YJ102 and CtBP1, and Phe102, Arg184 and His236 of CTBP1 are important for the interaction between YJ103 and CTBP1 (Fig. 3B).
[0165] 1-4. Confirmation of target genes of CTBP-YJ102 To identify the target genes of CtBP1-YJ102 in human UCB-MSCs, chromatin immunoprecipitation (ChIP) analysis was performed. Specifically, human UCB-MSCs were cultured in a 100 mm culture dish at 2 × 10 6The next day, 10 ul of YJ102 (30 mM) or DMSO (control group) was treated and cultured for 2 days. For cross-linking and DNA sharing, formaldehyde was added to the culture dish in which UCB-MSCs were cultured to a concentration of 1%, and the dish was fixed by incubating at 37°C for 10 minutes. The culture medium was removed, and the cells were washed twice with PBS containing protease inhibitors to collect the cells. The dish was centrifuged at 3000 rpm for 5 minutes at 4°C, and the supernatant was removed. SDS-disruption buffer containing protease inhibitors was added, incubated on ice for 10 minutes, and the cells were disrupted by ultrasonication. The dish was centrifuged at 13,000 rpm for 10 minutes at 4°C, and the supernatant was transferred to a new microcentrifuge tube and 1 / 10 volume of ChIP Dilution Buffer was added. Next, DNA was purified and agarose gel electrophoresis was performed to confirm that DNA was shared at 200-1000 bp. For chromatin immunoprecipitation, the Protein G agarose slurry was washed with PBS, blocked with 1 ml of 1% BSA, washed with PBS, and then sonicated with cell homogenate. Primary antibodies, anti-CtBP1 antibody (Cat. 07-306, Millipore), anti-LSD1 antibody (Cat. A1156, Abclonal), and normal rabbit IgG (Cat. 12-370, Merck Millipore) (control group) were added at 1 ug each and incubated overnight at 4°C on a rotator.
[0166] The next day, the supernatant was removed by centrifugation, and the DNA-antibody-agarose beads were washed once with Low Salt Immune Complex Wash Buffer, High Salt Immune Complex Wash Buffer, and LiCl Immune Complex Wash Buffer, and then washed twice with 1X TE. 250 μl of elution buffer (1% SDS, 0.1M NaHCO3) was added to the DNA-antibody-agarose beads, and the beads were incubated at room temperature for 15 minutes using a rotator, and then centrifuged to transfer the supernatant to a new microcentrifuge tube. The above elution process was repeated once more, and the eluate was mixed. 20 μl of 5M NaCl was added to the eluate, which was then heated at 65° C. for 4 hours, and then 10 μl of 0.5M EDTA, 20 μl of 1M Tris-HCl (pH 6.5), and 2 μl of proteinase K (10 mg / ml) were added and incubated at 45° C. for 1 hour. Phenol / chloroform extraction and ethanol precipitation were performed, and the DNA pellet was resuspended in DW, followed by real-time quantitative PCR using the primers in Table 2 below.
[0167] [Table 2]
[0168] The results showed that YJ102 increased CtBP1 binding to the HES1 gene promoter and decreased HES1 expression (Fig. 4A), and that YJ102 increased the CtBP1-LSD1 complex binding to the Sox2 gene promoter and increased Sox2 expression (Fig. 4B).YJ102 also increased the amount of CtBP1-LSD1 complex binding to the OCT4 gene promoter, inducing OCT4 expression (Fig. 4C), and that YJ102 increased CtBP1 binding to the HES1 gene promoter and increased the CtBP1-LSD1 complex binding to the Sox2 and Oct4 gene promoters (Fig. 4D).
[0169] Example 2. Direct transdifferentiation into ciNSC5 by compounds of the present invention 2-1. Confirmation of differentiation of UCB-MSCs into ciNSC5 by YJ102 To confirm whether YJ102 induces CtBP1-mediated ciNSC5 differentiation in human UCB-MSCs, the mechanism of CTBP1 induction by NSC95397 or MTOB (4-methylthio-2-oxobutanoate) treatment was analyzed by immunochemistry. Specifically, UCB-MSCs were cultured at 2.1 × 10 4 cells / well (DMSO control group: 3.5 × 10 3 The next day, the cells were treated with 30uM YJ102, 10uM NSC95397 (Cat.93718-83-3, Merck) or 300uM MTOB (Cat.K6000, Merck) either alone or in combination (DMSO was used as a control) and cultured at 37℃ for 5 days. The culture medium was removed, the cells were washed with PBS, and then fixed with 4% paraformaldehyde at room temperature for 10 minutes. After washing three times with PBS, the cells were permeabilized with PBS-T containing 0.5% Triton X-100 for 10 minutes, washed three times with PBS-T for 10 minutes each, and then blocked with blocking solution (PBS-T containing 5% BSA and 5% goat serum) for 1 hour. Next, the cells were treated with anti-Tuj1 antibody (Cat. 801201, BioLegend) diluted 1 / 5000 in blocking solution and incubated overnight at 4℃. The next day, the cells were washed 10 times for 10 minutes with PBS-T, treated with anti-mouse IgG-cy3 (Cat. 111-165-003, Jackson ImmunoResearch) diluted 1 / 2000 in blocking solution and incubated for 1 hour in the dark. Next, the cells were washed 10 times for 10 minutes with PBS-T, mounted with mounting solution containing DAPI, and observed under a confocal microscope.
[0170] The results showed that Tuj1 expression in YJ102-treated ciNSC5 differentiated from UCB-MSCs by YJ102 was reduced by NSC95397, which inhibits the binding of proteins with PxDLS motifs to CtBP (Figure 5A), and that Tuj1 expression was reduced by MTOB, which suppresses the transcriptional activity of CtBP (Figure 5B).
[0171] Through this, we confirmed that YJ102 differentiates UCB-MSCs into neural progenitor cells, ciNSC5, through regulating CtBP1.
[0172] 2-2. Direct transdifferentiation of UCB-MSCs into ciNSC5 by YJ101, YJ102, or YJ103 To confirm whether the compounds YJ101, YJ102, and YJ103 of the present invention directly transdifferentiate UCB-MSCs into Tuj1-positive neural progenitor cells, ciNSC5, we performed immunochemical analysis. Specifically, UCB-MSCs were cultured at 2.1 × 10 4 cells / well (DMSO control group: 3.5 × 10 3YJ101, YJ102 and YJ103 were dissolved in DMSO at 30mM, and then treated with 30uM of each (DMSO was used as a control) and cultured at 37℃ for 5 days. The culture medium was removed, washed with PBS, and fixed with 4% paraformaldehyde at room temperature for 10 minutes. After washing three times with PBS, the cells were permeabilized with PBS-T containing 0.5% Triton X-100 for 10 minutes, washed three times with PBS-T for 10 minutes each, and blocked with blocking solution (PBS-T containing 5% BSA and 5% goat serum) for 1 hour. Next, the cells were treated with anti-Tuj1 antibody (Cat.801201, BioLegend) diluted 1 / 5000 in blocking solution and incubated at 4℃ overnight. The next day, the cells were washed 10 times with PBS-T for 10 minutes each, and then treated with anti-mouse IgG-FITC diluted 1 / 500 in blocking solution and incubated for 1 hour in the dark. Then, the cells were washed 10 times with PBS-T for 10 minutes each, mounted with mounting solution containing DAPI, and observed under a confocal microscope.
[0173] The results showed that the expression of Tuj1 was increased in ciNSC5 differentiated from UCB-MSCs by YJ101, YJ102, and YJ103 ( Figure 6 ), confirming that all of YJ101, YJ102, and YJ103 directly induced trans-differentiation from UCB-MSCs to ciNSC5.
[0174] 2-3. Confirmation of direct transdifferentiation of mesenchymal stem cells of different origins by YJ101, YJ102 or YJ103 To confirm whether direct transdifferentiation into neural progenitor ciNSC5 occurs similarly when human UCB-MSCs are treated with YJ101, YJ102, or YJ103 for 5 days, the expression of neural markers was examined by immunochemical analysis in ciNSC5 cells differentiated using human adipose-derived mesenchymal stem cells (AD-MSCs), human bone marrow-derived mesenchymal stem cells (BM-MSCs; ATCC), and human umbilical cord blood-derived mesenchymal stem cells (UCB-MSCs; Promo Cell). Specifically, AD-MSCs (StemPro Human Adipose-Derived Stem Cells, Gibco, Passage #6) were cultured in MesenPRO RS medium, BM-MSCs (ATCC, Passage #6) in Mesenchymal Stem Cell Basal Medium for Adipose, Umbilical and Bone Marrow-derived MSC (Cat. PCS-500-030, ATCC) medium, and UCB-MSCs (Promo Cell, Passage #6) in CellCor CD MSC (Cat. YSP001, Xell Therapeutics) medium. Then, 2.1 × 10 cells were cultured on 12-well plates containing 18 mm circular cover glasses. 4 cells / well (DMSO control group: 3.5 × 10 3YJ101, YJ102 and YJ103 were dissolved in DMSO at 30mM and treated with the cells at 10, 20 or 30uM (DMSO-treated UCB-MSCs were used as a control group) and cultured at 37℃ for 5 days. The culture medium was removed, washed with PBS, and fixed with 4% paraformaldehyde at room temperature for 10 minutes. After washing three times with PBS, the cells were permeabilized with PBS-T containing 0.5% Triton X-100 for 10 minutes, washed three times with PBS-T for 10 minutes each, and blocked with blocking solution (PBS-T containing 5% BSA and 5% goat serum) for 1 hour. Next, the cells were treated with anti-Tuj1 antibody (Cat.801201, BioLegend) diluted 1 / 5000 in blocking solution and incubated at 4℃ overnight. The next day, the cells were washed 10 times with PBS-T for 10 minutes each, treated with anti-mouse IgG-cy3 diluted 1 / 2000 in blocking solution, and incubated in the dark for 1 hour. Then, the cells were washed 10 times with PBS-T for 10 minutes each, mounted with mounting solution containing DAPI, and observed under a confocal microscope.
[0175] The results showed that Tuj1 expression was increased in ciNSC5 differentiated from AD-MSCs by YJ101, YJ102, and YJ103 (Figure 7A), that Tuj1 expression was also increased in ciNSC5 differentiated from BM-MSCs by YJ101, YJ102, and YJ103 (Figure 7B), and that Tuj1 expression was also increased in ciNSC5 differentiated from UCB-MSCs by YJ101, YJ102, and YJ103 (Figure 7C).
[0176] 2-4. Confirmation of compound cytotoxicity The cytotoxicity of YJ101, YJ102 and YJ103 was confirmed in human UCB-MSCs using the Caspase-Glo® 3 / 7 Assay System (Cat. G8091, Promega). Specifically, UCB-MSCs were dispensed into each well of a 96-well plate at 100 μl (6,000 cells), and YJ101, YJ102 and YJ103 were dissolved in DMSO at 30 mM, and then treated with the cells at concentrations of 10, 20 or 40 μM (DMSO treatment was used as the control group) and cultured at 37°C for 3 or 5 days. Compound plates were prepared by serial dilution starting from 40 μM in a 96-well plate. The highest dose was plated in rows 4, 8 and 12, and DMSO (vehicle control) was plated in rows 1, 5 and 9 (Table 3). The compound plate was mixed on a shaker for 1 minute, and the medium of the 96-well plate into which UCB-MSC was dispensed was removed, and then 100 μl of compound solution was treated and cultured at 37 ° C for 3 and 5 days. Next, 100 μl of Caspase-Glo 3 / 7 reagent prepared by mixing Caspase-Glo 3 / 7 Buffer with Caspase-Glo 3 / 7 substrate was added to each well of the 96-well plate, and the plate was covered and then shaken at 300 to 500 rpm for 30 seconds to mix. Next, the plate was incubated at room temperature for 30 minutes, and the luminescence was measured using a plate-reading luminometer, and the floating was calculated using the following formula 2.
[0177] [Table 3]
[0178]
number
[0179] The results showed that none of the compounds of the present invention, YJ101, YJ102, and YJ103, induced cell apoptosis in UCB-MSCs ( FIG. 8 ).
[0180] 2-5. Confirmation of the effect of compounds on MSC proliferation To confirm the effect of YJ101, YJ102 and YJ103 on MSC proliferation, 100μl (6,000 cells) of UCB-MSC was dispensed into each well of a 96-well plate, and YJ101, YJ102 and YJ103 were dissolved in DMSO at 30mM, and the cells were treated with YJ101, YJ102 and YJ103 at a concentration of 10, 20 or 40uM (DMSO treatment was used as a control group) and cultured at 37℃ for 3 or 5 days. Compound plates were prepared in the same manner as in Examples 2-4. After removing the medium from the 96-well plate containing UCB-MSC, 100μl of compound solution was added and the cells were cultured at 37℃ for 3 or 5 days. Next, 100μl of CellTiter-Glo reagent, which was prepared by mixing CellTiter-Glo Buffer with CellTiter-Glo substrate, was added to each well of the 96-well plate, and the plate was covered and incubated at room temperature for 30 minutes. Then, the luminescence was measured using a plate-reading luminometer, and the luminescence was calculated according to the following equation 3 and floated.
[0181]
number
[0182] As a result, all of the compounds of the present invention, YJ101, YJ102 and YJ103, decreased cell proliferation in a concentration-dependent manner (FIG. 9). Generally, cell proliferation decreases during cell differentiation.
[0183] Example 3. Characteristics of ciNSC5 directly trans-differentiated by the compounds of the present invention 3-1.Expression of neural markers in ciNSC5 The expression of neural markers in ciNSC5 (chemically induced neural stem cell 5), which was directly transdifferentiated from human UCB-MSCs by treating with YJ102 for 5 days as described in Example 2, was confirmed by immunochemical analysis and Western blot analysis. Specifically, for immunochemical analysis, UCB-MSCs were placed in a 12-well plate containing an 18 mm cover glass at 2.1 × 10 4 cells / well (DMSO control group: 3.5 × 10 3The day after dispensing, YJ102 was dissolved in DMSO at 30 mM and treated with the cells at a concentration of 30 μM (DMSO was used for the control group) and cultured at 37°C for 5 days. The culture medium was removed, the cells were washed with PBS, and then fixed with 4% paraformaldehyde at room temperature for 10 minutes. After washing three times with PBS, the cells were permeabilized with PBS-T containing 0.5% Triton X-100 for 10 minutes, washed three times with PBS-T for 10 minutes each, and then blocked with blocking solution (PBS-T containing 5% BSA and 5% goat serum) for 1 hour. Next, primary antibodies diluted in blocking solution were used: anti-Tuj1 antibody, anti-TBR2 antibody (Cat. Ab23345, Abcam), anti-MASH1 antibody (Cat. Ab74065, Abcam), anti-GAP43 antibody (Cat. Ab16053, Abcam), anti-p75 antibody (Cat. G323A, Promega), and anti-MAP2 antibody (Cat. 4542, Cell Signaling Technology, Inc.). signaling), anti-NSE antibody (Cat.AB951, Chemicon), anti-NeuN antibody (Cat.MAB377, Chemicon), anti-Calretinin antibody (Cat.180211, Invitrogen), anti-Doublecortin antibody (Cat.Ab18723, abcam), anti-NeuroD1 antibody (Cat.Ab213725, abcam), anti-Nestin antibody (Cat.Ab18102, abcam), anti-Musashi 1 antibody (Cat.AB5977, Chemicon) and anti-GFAP antibody (Cat.G3893, Sigma) were treated and incubated overnight at 4°C. The next day, the cells were washed 10 times with PBS-T for 10 minutes each, and then treated with anti-mouse IgG-cy3 or anti-rabbit IgG-cy3 (Cat. 111-165-003, Jackson ImmunoResearch) diluted in blocking solution and incubated for 1 hour in the dark. Then, the cells were washed 10 times with PBS-T for 10 minutes each, mounted with mounting solution containing DAPI, and observed under a confocal microscope.For Western blot analysis, the culture medium was removed and the cells were washed with PBS, then disruption buffer (1% Nonidet® P-40, 20 mM Tris (pH 8.0), 137 mM NaCl, 0.5 mM EDTA, 10% glycerol, 10 mM Na2P2O7, 10 mM NaF, 1 μg / ml aprotinin, 10 μg / ml leupeptin, 1 mM vanadate and 1 mM PMSF) was added, the cells were collected using a scraper, rocked at 4°C for 20 minutes, and centrifuged at 12,000 rpm for 30 minutes. After centrifugation, the supernatant was transferred to another e-tube, and the protein was quantified using a BCA analysis kit, and the same amount of protein was loaded onto SDS-PAGE and electrophoresed. Next, the cells were transferred to Nitrocellulose membranes and Western blots were performed according to the protocols provided in the antibody data sheets for the primary antibodies: anti-CD325 (Cat. 10-0224, Invitrogen), anti-p75, anti-GAP43, anti-CD54 (Cat. 67836, Cell signaling), anti-CD309 (Cat. MA5-15157, Invitrogen), anti-CD56 (Cat. A7913, Abclonal), anti-PSA-NCAM (Cat. 5324, Millipore), anti-CD29 (Cat. Ab183666, Abcam), anti-MASH1, anti-TBR2, anti-CD44, anti-CD73, and anti-CD105.
[0184] Immunoassay results showed that ciNSC5, which was directly trans-differentiated from human UCB-MSCs by treatment with YJ102 for 5 days, expressed neural progenitor markers Tuj1, TBR2, MASH1, GAP-43, and p75, but did not express mature neuronal markers MAP2, NSE, and NeuN. It also did not express doublecortin and NeuroD1 (Neurogenic differentiation 1), which are known to be expressed during the early differentiation process of neurons, and did not express early neural stem cell markers Nestin, Mussashi 1, and GFAP (Figure 10). In addition, Western blot analysis of neural progenitor cell marker proteins showed that, compared with MSCs, ciNSC5 had more than six times (approximately 6-8 times) more Tuj1 protein, more than seven times (approximately 7-10 times) more CD325 (N-cadherin) protein, more than four times (approximately 4-8 times) more p75 protein, more than four times (approximately 4-7 times) more GAP43 protein, more than two times (approximately 2-5 times) more CD54 protein, more than three times (approximately 3-7 times) more CD309 protein, and more than 3.5 times (approximately 4-7 times) more CD56 (NCAM) protein. , 3.5-6 fold), PSA-NCAM protein increased more than four-fold (approximately, 4-6 fold), CD29 protein increased more than 4.5-fold (approximately, 4.5-8 fold), MASH1 protein increased more than four-fold (approximately, 4-8 fold), and TBR2 protein increased more than three-fold (approximately, 3-7 fold) (Figures 11 and 13). Meanwhile, the protein expression of MSC markers CD44, CD73, and CD105 was shown to be decreased by more than 90%, 50%, and 80%, respectively, in ciNSC5 compared to MSCs (Figures 12 and 13).
[0185] 3-2. Analysis of secreted proteins of ciNSC5 Western blot and ELISA analyses were performed to confirm the therapeutic effect of ciNSC5, which was directly trans-differentiated from human UCB-MSCs by treating with YJ102 for 5 days as described in Example 2, through the secretion of growth factors, tissue degradation, and neural differentiation / regeneration-related factors. 5 Dispense cells / well (DMSO control: 5 × 10 4 The next day, YJ102 was dissolved in DMSO at 30 mM and treated with the cells at a concentration of 30 μM (DMSO treatment was used for the control group) and cultured at 37°C for 5 days to obtain cell lysates of ciNSC5 differentiated from UCB-MSC. In addition, the culture medium was removed from ciNSC5 differentiated from UCB-MSC, and the cells were washed with PBS and subcultured, and new culture medium without YJ102 was added and cultured at 37°C for 2, 4, and 7 days. Next, each cell was lysed and Western blot analysis was performed. Western blot analysis was then performed on the cell lysates and culture medium of ciNSC5. The antibody information used in the analysis is shown in Tables 4 and 5.
[0186] [Table 4]
[0187] [Table 5]
[0188] As a result, in the case of ciNSC5 differentiated from UCB-MSC by treatment with YJ102, it was shown that the growth factors PlGF and VEGFA (VEGF-A), and the tissue degradation factors MMP1, MMP2, MMP7, and TIMP2 were increased in ciNSC5 compared to MSCs, and that SHH and Notch1, among the ligands involved in neural differentiation, neurogenesis, and axon regeneration, were increased (Figures 14 and 15). In addition, when ciNSC5 differentiated from UCB-MSC by YJ102 treatment was passaged and cultured in a medium without YJ102 for 2 days, the growth factors increased in the ciNSC5 culture medium compared to MSCs were PlGF, NGF, BDNF, and VEGFA (PlGF: 2.5 times, NGF: 3.8 times, BDNF: 2 times, and VEGFA: 2.1 times), and the cytokines TNFSF12 and IL-16 were increased (Figures 16 and 17). In addition, the tissue degradation factors MMP1 and MMP2 were increased, as were MMP7 and TIMP2, and among the ligands involved in neural differentiation, neurogenesis, and axon regeneration, SHH and Notch1 were increased (Figures 16 and 17). In addition, after ciNSC5 was cultured for 4 or 7 days in a medium without YJ102, the proteins in the medium were examined by Western blot analysis, and it was shown that the secretion of growth factors, tissue degradation, and neural differentiation / regeneration-related proteins changed as shown in Figures 18 and 19. In addition, the amounts of VEGFA, MMP-2, NGF, MMP1, PlGF, and TNFSF12 among the growth factors and tissue degradation-related factors shown to be increased in ciNSC5 in the Western blot analysis were examined in the medium after ciNSC5 was cultured for 2 days in a medium without YJ102, and it was shown that the amounts of VEGFA, MMP-2, NGF, MMP1, PlGF, and TNFSF12 secreted into the ciNSC5 medium were significantly increased compared to the amounts observed in the MSC medium (Figures 20 and 21).
[0189] 3-3. Analysis of genes expressed in ciNSC5 using RNA-seq We analyzed the gene expression profile of ciNSC5, which was directly trans-differentiated from human UCB-MSCs by YJ102 treatment for 5 days, using genome-wide RNA-seq. 5 After dispensing (control group: 1.67 × 10 4The cells were treated with 30 μM of YJ102 dissolved in DMSO (DMSO treatment was used for the control group) and cultured at 37°C for 2, 3 or 5 days. The culture medium was then removed and washed with PBS, and the cells were collected with a scraper and transferred to a microcentrifuge tube. The PBS was removed by centrifugation, and 500 μl of Tri-RNA Reagent was added and mixed well by pipetting. 100 μl of chloroform was added and the tube was vortexed for 15 seconds and then centrifuged at 14,000 rpm for 20 minutes at 4°C. The upper aqueous phase was then transferred to a new microcentrifuge tube using a pipette, and 550 μl of isopropanol was added and mixed. The cells were centrifuged at 14,000 rpm for 20 minutes at 4°C, the supernatant was discarded, and the pellet was washed with 1 ml of 70% ethanol. The cells were centrifuged at 14,000 rpm for 2 minutes and the supernatant was discarded. The pellet was air-dried, and RNA was dissolved in 50μl RNase-free DIW. 1μl DNase was added and incubated at 37℃ for 30 minutes. The same volume of 8M LiCl was then added and placed on ice for 1 hour, centrifuged at 14,000 rpm at 4℃ for 10 minutes, washed with 70% ethanol, and air-dried. The pellet was resuspended in 100μl RNase-free DIW, centrifuged at 14,000 rpm at 4℃ for 10 minutes, the supernatant was removed, the pellet was air-dried, and the RNA concentration was quantified using nanodrop. Next, RNAseq was performed using Theragen Bio, and the gene expression levels between samples were compared using FPKM (Fragments Per Kilobase of transcript per Million). To verify accuracy, significant gene ontology classifications were selected based on genes with a p-value of less than 0.05 using Fisher's method, and genes that were increased more than 2-fold or decreased less than 0.5-fold compared to DMSO-treated UCB-MSCs were selected for functional analysis.The gene expression program file was displayed as a heat map with three colors, RGB (red, green, black), according to the expression value (Figure 22), and a trend analysis was performed by checking the Gene Ontology (GO) using Reactome, a gene function database.
[0190] RNA-seq results showed that the expression of cell division-related genes decreased and the expression of nervous system-related genes increased in UCB-MSCs treated with YJ102 for 3 days. Based on this, genes involved in neurogenesis, synapses, neurotransmitters, nerve growth factors, etc., among factors whose expression changed in the medium on the 5th day, were selected and analyzed. The results showed that the expression of genes that induce neurogenesis (transcription factors, ligands, and receptors) and genes involved in the secretion of brain-derived neurotrophic factors for nerve regeneration and neuroprotection was prominent in ciNSC5 (Figures 23 and 24).
[0191] 3-4. Analysis of genes expressed in ciNSC5 using real-time RT-PCR The expression of the genes selected based on the RNA-seq analysis results in Example 3-3 was confirmed by real-time RT-PCR to confirm the expression profile of the genes in MSCs and ciNSC5. 5 After dispensing (control group: 1.67 × 10 4 The cells were treated with YJ102 dissolved in DMSO at a concentration of 30 μM (the control group was treated with DMSO) and cultured at 37° C. for 5 days. RNA was then extracted and quantified in the same manner as in the previous example.
[0192] As a result, the expression of enzymes for decomposing glial scars was significantly increased in ciNSC5 differentiated from UCB-MSCs treated with YJ102 for 5 days compared to the control group (Figure 25), and the expression of transcription factors related to neurogenesis was also increased compared to the control group (Figure 26).In addition, the expression of neuronal markers such as myelination, synapsis, matrix / cell adhesion, and calcium signaling was also increased compared to the control group (Figure 27), and the expression of neuronal receptors and channels was also increased compared to the control group (Figure 28).
[0193] Through this, we found that YJ102 treatment induced various neurogenesis gene programs and secreted molecules related to neurogenesis and exon regeneration. We also confirmed that YJ102 can increase the expression of enzymes that enable glial scar degradation in ciNSC5.
[0194] 3-5. Confirmation of changes in cell characteristics due to subculture of ciNSC5 The change in cell characteristics of ciNSC5 differentiated into human UCB-MSCs by YJ102 was examined by immunochemical analysis using Tuj1 antibody. 6The cells were then divided into 100 mm culture dishes and subcultured every 2 days for a total of 6 passages. The culture medium was then removed, washed with PBS, and fixed with 4% paraformaldehyde at room temperature for 10 minutes. After washing 3 times with PBS, the cells were permeabilized with PBS-T containing 0.5% Triton X-100 for 10 minutes, washed 3 times with PBS-T for 10 minutes each, and blocked for 1 hour with blocking solution (PBS-T containing 5% BSA and 5% goat serum). Next, the cells were treated with anti-Tuj1 antibody diluted 1 / 5000 in blocking solution and incubated overnight at 4°C. The next day, the cells were washed 10 times with PBS-T for 10 minutes each, and then treated with anti-mouse IgG-cy3 diluted 1 / 2000 in blocking solution and incubated for 1 hour in the dark. Next, the cells were washed 10 times with PBS-T for 10 minutes each, mounted with a mounting solution containing DAPI, and then observed under a confocal microscope.
[0195] As a result, it was shown that the doubling time was maintained even when ciNSC5 was passaged (Figure 29), and the cumulative population doubling level (CPDL) value was also maintained according to the passage number (Figure 30). In addition, the expression of Tuj1 was maintained even when ciNSC5 was passaged (Figure 31), and it was shown that there were no chromosomal abnormalities in ciNSC5 differentiated by YJ102 (Figure 32).
[0196] Through this, it was found that the cell characteristics of ciNSC5 were maintained even after subculture.
[0197] 3-6. Confirmation of differentiation of ciNSC5 into neural cells We confirmed whether ciNSC5 differentiated into human UCB-MSCs by YJ102 could differentiate into neural cells, and whether adipogenesis occurred by MDI (Methylisobutylxanthine, Dexamethasone, Insulin) treatment to investigate the differentiation stability of ciNSC5. Specifically, UCB-MSCs were cultured in a 100 mm culture dish at 3 × 105 Distribute cells / well (DMSO control group is 5 x 10 4 The next day, YJ102 was dissolved in DMSO at 30 mM and then treated with the cells at a concentration of 30 μM (DMSO-treated UCB-MSCs were used as the control group). The cells were cultured at 37°C for 5 days to obtain ciNSC5 differentiated from UCB-MSCs. Next, 5 × 10 ciNSC5 and control MSCs were each cultured at 5 × 10 5 The cells / dish were dispensed into 60 mm culture dishes, and the medium was replaced every 3 days to observe changes in morphology. To confirm whether ciNSC5 could differentiate into adipocytes, 5 × 10 MSCs and ciNSC5 were each dispensed at 10 × 10 5The cells were then dispensed into 60mm culture dishes at 1 cell / dish and cultured for 3 days in medium supplemented with MDI (0.5mM of 3-isobutyl-1-methylxanthine, 1uM dexamethasone, and 10ug / ml insulin), and then harvested. For immunochemical analysis, the culture medium was removed, washed with PBS, and fixed with 4% paraformaldehyde at room temperature for 10 minutes. After washing three times with PBS, the cells were permeabilized with PBS-T containing 0.5% Triton X-100 for 10 minutes, washed three times with PBS-T for 10 minutes each, and blocked for 1 hour with blocking solution (PBS-T containing 5% BSA and 5% goat serum). Next, anti-TH antibody (Cat.p40101-150, Pel-Freez) and anti-MAP2 antibody (Cat.4542, cell signaling) diluted in blocking solution were treated, and incubated overnight at 4℃. The next day, the cells were washed 10 times for 10 minutes with PBS-T, treated with anti-rabbit IgG-cy3 diluted in blocking solution, and incubated in the dark for 1 hour. The cells were then washed 10 times for 10 minutes with PBS-T, mounted with mounting solution containing DAPI, and observed under a confocal microscope. To extract RNA, the culture medium was removed, washed with PBS, and the cells were collected with a scraper and transferred to a microcentrifuge tube. After centrifugation to remove PBS, 500 μl of Tri-RNA Reagent was added and mixed well by pipetting. 100 μl of chloroform was added, the tube was vortexed for 15 seconds, and centrifuged at 14,000 rpm for 20 minutes at 4°C. The upper aqueous phase was then transferred to a new microcentrifuge tube using a pipette, and 550 μl of isopropanol was added and mixed. After centrifugation at 14,000 rpm for 20 min at 4°C and discarding the supernatant, the pellet was washed with 1 ml of 70% ethanol. After centrifugation at 14,000 rpm for 2 min, the supernatant was discarded. The pellet was air-dried and the RNA was dissolved in 50 μl RNase-free DIW. 1 μl DNase was added and incubated at 37°C for 30 min.Next, the same volume of 8M LiCl was added and placed on ice for 1 hour, centrifuged at 14,000 rpm at 4°C for 10 minutes, washed with 70% ethanol, and air-dried. The pellet was resuspended in 100μl RNase-free DIW, centrifuged at 14,000 rpm at 4°C for 10 minutes, the supernatant was removed, the pellet was air-dried, and the RNA concentration was quantified using a nanodrop. Next, 500ng of RNA was mixed with 2ul of PrimeScript RT Master Mix and the total volume was adjusted to 10ul with DW. cDNA was synthesized by reverse transcription at 37°C for 15 minutes, and the reverse transcriptase was inactivated by reacting at 85°C for 5 seconds. The expression of C / EBPα and PPARγ, which are markers of adipogenesis, was confirmed by real-time PCR using the synthesized cDNA.
[0198] The results showed that ciNSC5 differentiated into neural cells when cultured in differentiation medium (Figure 33), and unlike MSCs, did not respond to adipogenic induction (Figure 34).
[0199] Example 4. Confirmation of the therapeutic effect of ciNSC5 directly trans-differentiated by the compound of the present invention on Lou Gehrig's disease 4-1. Confirmation of increased life span in ALS model mice To confirm the effectiveness of ciNSC5 against Lou Gehrig's disease, we created ALS model mice, transplanted ciNSC5 into them, and then examined the life span of the mice. Specifically, transgenic ALS mice (B6SJL-Tg(SOD1-G93A)1Gur / J over-expressing human SOD1 containing the Gly93→Ala mutation, The Jackson Laboratory, Bar Harbor, ME, USA) were crossed with female mice of a similar background (B6 / SJLF1) to express SOD1 G93AA transgenic ALS mouse model was generated, and its offspring were analyzed for genotype of tail DNA using PCR assay. On the 60th day after birth, the mice were randomly grouped and anesthetized with chloral hydrate (500 mg / kg, intraperitoneally), and then 10 μl of MSCs suspended in saline or ciNSC5 (1 × 10 6 cells) differentiated into human UCB-MSCs by 5-day treatment with YJ102 were added. 6 The researchers injected 100 μg / ml of 10 ... As a result, the lifespan of both the MSC-transplantation group and the ciNSC5-transplantation group was increased compared to the saline-treated group. In particular, the lifespan of the ciNSC5-transplanted group was extended by 12 days compared to the saline-transplantation group and by 9 days compared to the MSC-transplantation group (Figure 35).
[0200] 4-2. Confirmation of ALS onset and delayed progression of motor symptoms After transplantation of ciNSC5 into the ALS model mice, behavioral tests were performed every 5 days from the 75th day after birth to confirm the motor function of the mice. The behavioral tests included the Rotarod test, motor score, hanging wire test, and balance beam test. For the Rotarod test to evaluate the general motor coordination, strength, and balance of the mice, the mice were trained on the Rotarod device (4-40 rpm, 180 sec) from 3 days before the test, and during the test, each mouse exercised on the Rotarod for 180 seconds, and the time it took for the mouse to fall off the Rotarod during the exercise was recorded. A total of 3 tests were performed per mouse, with a rest interval of 10 minutes or more between tests. The average score for each mouse was determined based on the 3 records. The locomotor score was determined by checking the condition of the hind limbs when the mouse's tail was lifted, and a score of 0-4 was assigned based on the following criteria: [4 points = normal; 3.5 points = onset of hind limb splay defect; 3 points = abnormal gait; 2 points = partial hind limb paralysis (first sign of limping); 1 point = hind limb paralysis and forelimb weakness; 0 point = forelimb paralysis of a similar degree to that of the hind limbs]. In addition, to perform the hanging wire test to evaluate the neuromuscular strength of the legs maintained against gravity, each mouse was placed on a wire lead in a normal housing case and the lead was inverted back and forth. The test was performed for a total of 180 seconds, and the time it took for the mouse suspended on the wire lead to fall to the floor was measured. A total of three tests were performed per mouse, with a rest interval of at least 10 minutes between tests. The average value of the three records was determined as the score for each mouse.In addition, for the balance beam test, mice were placed on a round wooden beam (0.5 cm diameter, 100 cm long, and 60 cm high) and their ability to maintain balance was scored from 0 to 6 based on the following criteria: [0 points = the mouse cannot stand on the beam for 30 seconds; 1 point = the mouse can stand on the upper right corner of the beam for 30 seconds; 2 points = the mouse cannot walk but can turn left or right on the beam; 3 points = the mouse can turn left or right on the beam and take more than one step; 4 points = the mouse can cross the beam with more than 50% foot slides of the affected hind limbs; 5 points = the mouse can cross the beam with less than 50% foot slides of the affected hind limbs; 6 points = the mouse can cross the beam with less than one foot slide].
[0201] The rotarod test results showed that there was no significant difference between the saline-treated group and the MSC-transplanted group, but the ciNSC5-transplanted group showed a significantly delayed decline in motor ability compared with both the saline-transplanted group and the MSC-transplanted group (saline group 12.8±5.8, MSC group 21.8±9.0, and ciNSC5 group 107.4±22.7 for 120 days) (Figure 36A). In addition, the motor score showed that SOD1 G93AIn transgenic mice, the motor score began to decrease from day 90 and continued to decrease until the end point, and MSC-transplanted mice showed a slightly higher score than saline-treated mice, but the difference was not significant, whereas the ciNSC5-transplanted mice group showed a decrease in motor score after day 120, and the motor score during the experimental period was significantly higher than both the saline and MSC groups (saline group 2.1±0.4, MSC group 2.3±0.4, and ciNSC5 group 3.7±0.2 for 120 days) (Figure 36B). In addition, in the hanging wire test, the saline-transplanted and MSC-transplanted mice began to fall off the wire from day 80, but the onset of the disease was delayed to the extent that some mice transplanted with ciNSC5 were observed to fall off after day 95. In addition, the ciNSC5 transplant group showed significantly higher scores than the other two groups throughout the entire hanging wire test (120-day saline group: 6.4±2.8, MSC group: 22.9±15.14, and ciNSC5 group: 113.1±18.2) (FIG. 36C).In addition, the ciNSC5 transplant group showed significantly higher scores than the other two groups from 85 days after birth until the end of the experiment (120-day saline group: 1.5±0.32, MSC group: 2.3±0.5, and ciNSC5 group: 4.0±0.5) (FIG. 36D).
[0202] 4-3. Confirmation of the effect of suppressing the loss of motor neurons in the spinal cord To determine whether ciNSC5 transplantation could alleviate the lumbar spinal cord neuronal loss associated with the clinical symptoms of ALS, Cresyl violet staining was performed 110 days after transplantation, and the number of motor neurons in the lumbar spinal cord was counted.
[0203] The results showed that saline-treated SOD1 mice had an average of 7711.3 ± 193.8 motor neurons compared with wild-type mice. G93AThe transgenic mice showed a significant decrease in the number of motor neurons (3875.1 ± 465), and the MSC-transplanted mice showed a slight increase in the number of motor neurons compared to the saline-treated mice, but the difference was not significant. However, the number of motor neurons in the ciNSC5-transplanted mice group was significantly increased compared to the saline-treated or MSC-transplanted groups (Figure 37).
[0204] Through this, ciNSC5 inhibits SOD1 G93A In a transgenic ALS mouse model, the death of motor neurons in the spinal cord was significantly suppressed compared to both saline- and MSC-treated groups, delaying the progression of Lou Gehrig's disease symptoms accompanied by motor dysfunction and extending the lifespan of ALS mice.
[0205] Example 5. Confirmation of the therapeutic effect of ciNSC5 directly trans-differentiated by the compound of the present invention on multiple sclerosis 5-1. Confirmation of improvement in behavioral symptoms in EAE mice We confirmed the efficacy of ciNSC5 in an experimental autoimmune encephalomyelitis (EAE) mouse model, which is a canonical model of multiple sclerosis (MS). Specifically, female adult C57BL / 6NTac mice (8-9 weeks old; 19-21 g) were purchased from Narabiotec Co., Ltd. (Seoul, Republic of Korea) and subcutaneously immunized with 200 ng MOG35-55 peptide (Sigma-Aldrich, St. Louis, MO, USA) in Complete Friends' Adjuvant (Sigma-Aldrich) containing 4 mg / ml sterile Mycobacterium tuberculosis (Difco) to induce EAE. On days 0 and 2, 200 ng pertussis toxin (Sigma-Aldrich), which plays a major role in stimulating the immune response, was injected intraperitoneally (Figure 38A). Eight days after MOG injection, mice were anesthetized with chloral hydrate (500 mg / kg, intraperitoneally) and injected with 10 μl of MSCs or ciNSC5 (1 × 10 6 Cells were injected into the cisterna magna. The control group was injected with the same amount of saline at the same time point. Thereafter, behavioral symptoms of the EAE mouse model were evaluated daily using a standard score ranging from 0 to 7 as follows: score 0 = no symptoms; score 1 = partial tail droop; score 2 = moderate waddling gait; score 3 = moderate to severe hind limb weakness; score 4 = bilateral paralysis; score 5 = bilateral paralysis with moderate forelimb weakness; score 6 = quadriplegia, moribund; score 7 = death. Behavioral analysis results were analyzed using repeated assessment ANOVA (time vs treatment).
[0206] As a result, mice in the saline-treated control group started to show typical behavioral symptoms, including tail droop and leg paralysis, which demonstrated the progression of paralysis 8-9 days after EAE induction (initiation step), and reached a peak on days 18-20, which persisted until the end of the experiment (Figure 38B). Meanwhile, the MSC or ciNSC5 transplanted groups showed significantly alleviated behavioral symptoms of EAE even at the initiation step, and in particular, the clinical scores of the ciNSC5 transplanted group were significantly lower than those of the MSC transplanted group (saline group 2.7±0.2, MSC group 2.1±0.2, and ciNSC5 group 1.5±0.2 on day 9 after transplantation) (Figures 38B and D). There was no significant difference in body weight among the experimental groups during the experimental period (Figure 38C).
[0207] 5-2. Confirmation of CNS demyelination inhibitory effect Thirty days after MOG injection, mice were anesthetized with chloral hydrate (500 mg / kg) and perfused via cardiac puncture with 0.1 M PBS (pH 7.4) followed by 4% paraformaldehyde in 0.1 M PBS (pH 7.4). Lumbar segments of the spinal cord were dissected and post-fixed in the same fixative for 6 h and placed in 30% sucrose in 0.1 M PBS (pH 7.4). Segments were cryosectioned in OCT and transverse sections were cut at 16 μm using a cryostat (Leica, Germany). For molecular studies, animals were perfused with PBS and sections of the lumbar spinal cord (L4-L5) were isolated and frozen at -80°C until use. Frozen sections were analyzed by immunohistochemistry using antibodies against GFAP (DAKO, Santa Clara, CA, USA), CD11b (Millipore, Billerica, MA), and CD68 (Millipore). For double labeling, FITC- or cy3-conjugated secondary antibodies were used (Jackson ImmunoResearch, West Grove, PA), and nuclei were labeled with DAPI (Molecular Probes, Eugene, OR). Immunostaining control studies were performed by replacing the primary antibody with a non-immune, control antibody and stripping off the primary antibody by preadsorption with an excess (10 μg / ml) of each antigen. Fluorescence intensities above titers were quantified and averaged using MetaMorph software (Molecular devices, Sunnyvale, CA). Titer values were background at least in triplicate, and background was quantified and averaged for primary antibody stripping controls. In addition, for Western blot analysis, frozen spinal cord tissues were homogenized in homogenization buffer (1% Nonidet® P-40, 20 mM Tris (pH 8.0), 137 mM NaCl, 0.5 mM EDTA, 10% glycerol, 10 mM Na2P2O7, 10 mM NaF, 1 μg / ml aprotinin, 10 μg / ml leupeptin, 1 mM vanadate, and 1 mM PMSF).The samples were collected in e-tubes, rocked at 4°C for 20 minutes, and centrifuged at 12,000 rpm for 30 minutes. The supernatant was transferred to another e-tube, and protein quantification was performed using a BCA assay kit. The same amount of protein was loaded onto SDS-PAGE and electrophoresed. The samples were then transferred to Nitrocellulose membranes and Western blot analysis was performed according to the protocol in each antibody data sheet. Data are presented as mean ± SEM, and multiple comparisons between groups were performed using one-way ANOVA. Tukey's multiple comparison was used as post hoc analysis. p<0.05 was considered statistically significant. All statistical analyses were performed using SPSS 15.0 (SPSS Science, Chicago, IL).
[0208] As a result, demyelination, as assessed by luxol fast blue staining, was significantly increased in the white matter of the spinal cord of EAE mice 30 days after immunization (Figure 39A, Saline), whereas spinal cord demyelination was significantly reduced in ciNSC5-transplanted EAE mice (Figures 38A and B). Furthermore, ciNSC5-transplanted EAE mice showed a significantly reduced demyelination effect compared to MSC-transplanted EAE mice. To re-examine the demyelination-suppressing efficacy of ciNSC5, MBP (myelin basic protein) expression was confirmed by immunostaining and Weston blotting. As a result, MBP expression was significantly reduced in saline-administered EAE mice compared to sham mice, and the reduction of MBP in the spinal cord of ciNSC5-transplanted mice was significantly suppressed compared to saline- or MSC-transplanted mice (Figures 39C and D). Western blot results also showed that MBP expression was significantly higher in ciNSC5-transplanted mice than in the other two groups (saline-transplanted group or MSC-transplanted group) (Figure 39E and F). This confirmed that ciNSC5 suppresses CNS demyelination, a typical pathological feature of MS patients, thereby alleviating its extent and severity.
[0209] 5-3. Confirmation of the inhibitory effect on the infiltration of monocytes and macrophages into the spinal cord white matter Thirty days after MOG immunization, infiltration of mononuclear cells around small blood vessels in the spinal cord was detected by cresyl violet (Cat. C5042, Sigma) staining, and CD68-positive macrophages were identified by immunohistochemical staining.
[0210] The results showed that EAE mice showed intensive mononuclear cell infiltration around the white matter of the spinal cord (Figure 40A and B, saline), whereas MSC- or ciNSC5-treated groups showed reduced mononuclear cell infiltration into the spinal cord white matter in both thoracic (A) and lumbar (B) sections (Figure 40), confirming that ciNSC5 transplantation alleviates EAE-induced mononuclear cell infiltration into the spinal cord white matter. Also, D68-positive macrophages were observed in the white matter of saline-treated EAE mice, whereas the number of infiltrated macrophages was significantly reduced in the MSC- or ciNSC5-transplanted groups (Figure 41).
[0211] 5-4. Confirmation of the effect of inhibiting activation of microglia and astrocytes To confirm the effect of ciNSC5 on the activation of glial cells such as microglia and astrocytes in the spinal cord, immunohistochemistry analysis against CD11b (microglia marker) or GFAP (astrocyte marker) antibodies was performed 30 days after immunization.
[0212] As a result, the spinal cord of saline-treated EAE mice showed very strong GFAP immunoreactivity, confirming the activation of astrocytes in the spinal cord (Figure 42). On the other hand, in EAE mice transplanted with MSCs or ciNSC5, the activation of astrocytes in the spinal cord was significantly reduced, and GFAP fluorescence intensity was quantified, and the GFAP intensity was significantly reduced in both the MSC-transplanted group and the ciNSC5-transplanted group. In particular, ciNSC5 showed a significant suppression effect on GFAP expression compared to MSCs (Figure 42D). This indicates that ciNSC5 suppresses astrocyte activation in EAE mice. Furthermore, immunostaining with CD11b showed that the spinal microglia of EAE mice showed typical activation patterns, with enlarged cytoplasm and shortened branches (Figure 43A), whereas the activation patterns of microglia were significantly reduced in EAE mice transplanted with MSCs or ciNSC5. Notably, many resting forms of microglia with long and thin branches were observed in the ciNSC5-transplanted mice (Figure 43), indicating that microglial activation was suppressed by ciNSC5 transplantation in EAE mice.
[0213] Example 6: Confirmation of the therapeutic effect of ciNSC5 directly trans-differentiated by the compound of the present invention on Parkinson's disease 6-1. Confirmation of motor function recovery and improvement effect To confirm the effect of ciNSC5 on functional recovery in the chronic stage of PD animal model via 6-OHDA injection, adult Sprague-Dawley male rats (230-250g, Sam:TacN(SD)BR, Samtako, Osan, Korea) were weighed and anesthetized with chloral hydrate (500mg / kg, intraperitoneal injection). The rats were fixed in stereotaxic mode and injected with 8ug of 6-OHDA dissolved in 4μl of saline using a 33-gauge Hamilton syringe at a fixed position (Partial injury model: AP+0.7, ML+2.6, DV-4.5 from bregma; and Complete injury model: AP-2.2, ML+1.5, DV-8.0 from bregma) (Figure 44). Four weeks after 6-OHDA injection, rats were anesthetized with chloral hydrate (500 mg / kg, i.p.) and then stereotaxically fixed. 10 μl of MSCs or ciNSC5 (1 × 10 6 After subcutaneous injection of apomorphine (0.05mg / kg), the rats were placed in a transparent cylinder with a diameter of 40cm and allowed to adapt for 10 minutes. The rats were determined to have completed Parkinson's disease models if they rotated more than 4 times per minute for 10 minutes. To evaluate the efficacy of ciNSC5 in improving motor function in the partial injury model, a rotation test was performed every 2 weeks after cell transplantation. In the complete injury model, a stepping test was performed once a week from the second week after transplantation to confirm the recovery of motor function. Each of the rats' forelimbs was placed on a treadmill and observed by videotaping for 1 minute. The number of steps in the contralateral direction, where walking disorder occurred, and the ipsilateral direction, where normal walking was possible, were counted on the side opposite to the side where 6-OHDA was injected, and the contralateral steps were divided by the total steps to calculate the stepping percentage (%). Normal rats showed a stepping percentage of 50%, while Parkinson's disease-induced rats showed a value of less than 10%.
[0214] As a result, in the partial injury model, the number of rotations decreased as time passed after transplantation in MSC- and ciNSC5-transplanted retinoids, and the ciNSC5-transplanted retinoids showed a remarkable recovery of motor function from 2 to 6 weeks after transplantation compared to the saline-transplanted group (Fig. 45A). In the complete injury model, the saline-administered group showed no change compared to before transplantation, whereas the ciNSC5-transplanted group showed a remarkable increase in the frequency of step pins from 2 weeks after transplantation compared to the saline-administered group, and this effect continued until 6 weeks after transplantation (Fig. 45B).
[0215] 6-2. Confirmation of the effect of suppressing the loss of dopamine neurons Cells were transplanted into 6-OHDA-injected PD animal models, and after 4 or 6 weeks, rats were anesthetized with chloral hydrate (500 mg / kg) and perfused through cardiac puncture with 0.1 M PBS (pH 7.4) and then 4% paraformaldehyde in 0.1 M PBS (pH 7.4). Brains were removed and post-fixed in the same fixative for 24 hours, and placed in 30% sucrose in 0.1 M PBS (pH 7.4). Tissues embedded in OCT compound were cut at 40 μm using a cryostat (Leica, Germany), and tissues containing Substantia nigra were immunostained with an antibody against TH, a dopamine neuron marker, to perform immunohistochemical staining.
[0216] The results showed that the number of dopamine neurons remaining in tissues transplanted with ciNSC5 was significantly higher than in tissues transplanted with saline or MSCs (Figure 46).
[0217] 6-3. Confirmation of differentiation effect into TH-positive dopamine neurons Immunostaining was performed using the human-specific antibody STEM121 in the striatum of Rett mice 6 weeks after transplantation in the partial injury model. No STEM121-positive cells were observed in the MSC transplantation group (data not shown), but STEM121-positive cells were confirmed in the ciNSC5 transplantation group (Figure 47). This means that the transplanted ciNSC5 survived in the tissue even 6 weeks after transplantation. In addition, double immunostaining using STEM121 and TH antibodies confirmed that the STEM121-positive human cells in the tissue transplanted with ciNSC5 were TH-positive dopamine neurons (Figure 48), indicating that the transplanted ciNSC5 differentiated into dopamine neurons in the striatum.
[0218] Through this, ciNSC5 not only significantly improved behavioral symptoms in a 6-OHDA-induced PD model, but also inhibited the death of dopamine neurons, demonstrating greater therapeutic efficacy than MSCs. In particular, the transplanted neural precursor cells, ciNSC5, differentiated into dopamine neurons in the striatum, the transplant site, indicating that when ciNSC5 is transplanted into neural tissue, it can demonstrate therapeutic efficacy by replacing dopamine neurons that have been reduced by PD.
[0219] Example 7. Confirmation of the therapeutic effect of ciNSC5 directly trans-differentiated by the compound of the present invention on chronic spinal cord injury 7-1. Confirmation of motor function recovery and improvement effect To confirm the effect of ciNSC5 on functional recovery in the chronic stage after spinal cord injury, behavioral tests including BBB open field test, grid walk test, and footprint analysis were performed after ciNSC5 transplantation, and functional recovery index (FRI) analysis was performed by combining these. Specifically, to prepare a chronic spinal cord injury Rett model, adult Sprague-Dawley male and female Retts (230-250g, Sam:TacN(SD)BR, Samtako, Osan, Korea) were weighed before surgery and anesthetized with chloral hydrate (500mg / kg, intraperitoneal injection), the back and neck were shaved, and a laminectomy was performed at the T9-T10 level to expose the lower part of the spinal cord without damaging the tunica albicans. Next, the spine was stabilized by clamping the spinous processes at T8 and T11, and a moderate bruising injury (10 g × 25 mm) was inflicted on the dorsal surface of the exposed spinal cord to create a chronic spinal cord injury rett model. After injury, the rett was placed in a temperature- and humidity-controlled chamber overnight with the muscles and skin covered. After surgery, the rett was subcutaneously injected with replacement fluid (5 ml, lactated ringer) and injected with antibiotics (gentamicin, 5 mg / kg, intramuscular injection) once daily for 5 days after surgery. After injury, the retts were housed individually per cage to facilitate access to water and food. Body weights and the weights of remaining food and water were checked and recorded for all animals. Bladders were passively emptied three times a day until reflex micturition was established. Six weeks after spinal cord injury, the retts were anesthetized with chloral hydrate (500 mg / kg, i.p.) and injected with 10 μl of MSCs or ciNSC5 (1 × 10 6The rats were injected with 1000x1000 cells into the lesion cavity. The control group was injected with the same amount of saline at the corresponding time points. Behavioral analysis of the BBB open field test, grid walk test, and footprint analysis was performed once a week for 8 weeks after implantation. The BBB open field test was used to evaluate recovery after contusion injury in the Rett spinal cord by testing locomotor function using the following open field locomotor scores (Table 5) according to the Basso, Beattie, and Bresnahan (BBB) criteria, ranging from complete paralysis (score 0) to normal locomotion (score 21), with the BBB score used for functional recovery and locomotion testing in chronic SCI studies. The grid walk test also required the animals to walk on a horizontal runway of 1 m long metal grid bars 30 cm off the floor, and a defined 10 bar sector was selected to analyze. To prevent habituation to the fixed bar spacing, the bars in such sectors were arranged irregularly (1-4 cm apart) and changed every test section. The analysis was performed by counting the number of foot placement errors, and if the animal could not walk on its hind legs, it was allowed to make two errors per bar, resulting in a total of 20 errors, and the percentage of foot missteps per step was calculated. In addition, the footprint analysis was performed by dipping the front and back legs of the animals in non-toxic red and blue dyes, and then having them walk across a narrow box (1 m long and 7 cm wide), scanning the footprints, and analyzing the digitized images. In addition, the above three behavioral tests were integrated to compare the behavior at the time of cell transplantation and 8 weeks after transplantation, and the delta value of the locomotor function recovery at 8 weeks was calculated to quantify the steps of motor function recovery and derive a Functional Recovery Index (FRI). The standard points given in each behavioral experiment are shown in Table 6 below.
[0220] [Table 6]
[0221] [Table 7]
[0222] The results showed that both ciNSC5- and MSC-transplanted groups significantly increased the BBB mobility score after SCI (Figure 49A and D). In addition, the grid error rate (missteps per step) of ciNSC5 and all MSCs was even lower in the saline-treated group, and the percentage of missteps in the ciNSC5-transplanted group was significantly reduced compared to the MSC-transplanted group in both male and female rats (Figure 49B and E). At 14 weeks after injury (8 weeks after transplantation), both ciNSC5- and MSC-transplanted rats showed fairly consistent forelimb-hindlimb coordination and very little toe dragging. In contrast, the saline-treated group showed inconsistent forelimb-hindlimb coordination and many dragging in the ink trails of both hindlimb. In addition, the toe dragging in the ciNSC5-transplanted group was significantly reduced compared to the MSC-transplanted group (Figure 49C and F). In addition, functional recovery index (FRI) analysis showed that the FRI scores of ciNSC5 and MSC were significantly increased compared to the saline transplantation group, and in particular, the FRI score of the ciNSC5 transplantation group was significantly improved compared to the MSC transplantation group (Figures 50A, B, D, and E). No abnormal body weight changes due to transplantation of ciNSC5 and MSC were observed during the behavioral experiment (Figures 50C and F).
[0223] 7-2. Confirmation of the effect of reducing lesion volume and myelin loss Eight weeks after MSC or ciNSC5 transplantation, animals were anesthetized with chloral hydrate (500 mg / kg) and perfused through cardiac puncture with 0.1 M PBS (pH 7.4) and subsequently with 4% paraformaldehyde in 0.1 M PBS (pH 7.4). Spinal cord sections (1.5 cm) centered on the lesion site were dissected and post-fixed in the same fixative for 6 h and placed in 30% sucrose in 0.1 M PBS (pH 7.4). Segments were frozen in OCT and longitudinal or transverse sections were cut at 10 or 16 μm. To confirm the lesion volume using serial longitudinal sections (10 μm) through the dorsal-ventral axis of the spinal cord, sections were stained with Cresyl violet acetate every 50 μm and observed under a light microscope. Lesion area was determined using MetaMorph software (Molecular devices) using a low magnification lens (1.25X), and the area of each longitudinal level was determined and the total lesion volume was inferred as the average of the numerical integration of consecutive areas. Serial transverse cryosections (16 μm thick) were also mounted on glass slides to confirm myelin loss after injury. Selected slides were incubated overnight at 60°C with 0.1% Luxol fast blue (Solvent Blue 38; Sigma) acidified with 95% ethanol. Differentiation was performed with 0.05% lithium carbonate.
[0224] To confirm tissue loss after SCI, serial longitudinal sections were stained with Cresyl violet to measure lesion volume, and 8 weeks after transplantation, both ciNSC5- and MSC-treated groups showed significantly reduced total lesion volume compared to the saline-injected group, and the lesion volume was significantly further reduced in the ciNSC5-transplanted group compared to the MSC-transplanted group (Figures 51A and B). In addition, myelin loss after injury was confirmed by Luxol-fast blue staining, and both ciNSC5- and MSC-treated groups showed significantly reduced myelin loss compared to the saline-injected group, and the myelin loss was significantly further reduced in the ciNSC5-transplanted group compared to the MSC-transplanted group (Figures 51C and D).
[0225] 7-3. Confirmation of the effect of reducing gliotic scar formation To confirm the effect of ciNSC5 on gliotic scar formation, double immunostaining for GFAP and CSPG was performed. Since CSPG secreted from the densely packed scar formed within the lesion site after spinal cord injury is considered to be a chemical obstacle to axonal regeneration and functional recovery, the presence of CSPG was confirmed by staining with CS-56. Specifically, frozen sections were analyzed by immunohistochemistry using antibodies against GFAP (DAKO, Santa Clara, CA, USA) and CS-56 (CSPG, Millipore, Billerica, MA). For double labeling, FITC or cy3-conjugated secondary antibodies were used (Jackson ImmunoResearch, West Grove, PA), and nuclei were labeled with DAPI (Molecular Probes, Eugene, OR). Immunostaining control studies were performed by replacing the primary antibody with a non-immune control antibody and removing the primary antibody by pre-adsorption with an excess (10 μg / ml) of each antigen. Fluorescence intensities above titers were quantified and averaged using MetaMorph software (Molecular devices, Sunnyvale, Calif.). Titer values were background at least three times, and background was quantified and averaged against primary antibody omission controls.
[0226] The presence of CSPGs was confirmed by staining with CS-56, and the lesion area of the spinal cord in the saline-treated group was abundantly filled with CS-56 and GFAP-positive staining signals, whereas the intensity of both CSPGs and GFAP was significantly decreased in the MSC and ciNSC5-transplanted groups compared to the saline-treated group (Figure 52A-C). The results of confirming the GFAP level by Western blot showed that the GFAP level was significantly decreased in the ciNSC5-transplanted group compared to not only the saline group but also the MSC-transplanted group, similar to the immunostaining results (Figure 52D). This confirmed that ciNSC5 inhibits the formation of gliotic scars.
[0227] 7-4. Confirmation of the effect of improving axon regeneration To confirm the effect of ciNSC5 on the growth of corticospinal axons, we performed anticipatory axon tracing using BDA, and to confirm the extent of the extra descending axon pathways leading to the injury site, fluorogold (FG) was injected into the lesion site through the tail at 14 weeks after injury, and selected FG-labeled neurons were counted in the supraspinal nuclei. Specifically, 8 weeks after MSC or ciNSC5 transplantation, 12 rats (3 from the saline injection group, 5 from the MSC transplantation group, and 5 from the ciNSC5 transplantation group) were anesthetized with chloral hydrate (500 mg / kg) and the bone overlying the motor cortex was removed. 10% fluorescent-labeled biotinylated dextran amine (BDA; Molecular Probes, Eugene, OR) was injected into the motor cortex in eight locations (four locations per side) in both directions, and two weeks after BDA injection, the retinoids were perfused with 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4). Spinal cords were collected and cut longitudinally at 20 mm thickness on a cryomicrotome, and axonal regeneration was quantified under a 20x lens with a fluorescent microscope. Each section was aligned with a grid with lines drawn at 0, 500, 1000, 1500, 2000, 2500, and 3000 μm intervals, and the number of axons was counted at the angular distance from the ostial edge of the lesion cavity, and BDA-positive axons were counted in four tissues selected at 100 μm intervals, including the corticospinal tract. The total number of axons in each animal was averaged per group. The total number of axons present in four sections per animal was counted and averaged.To determine the extent to which extra descending axons lead to lumbar expansion at the porolateral side by retrograde tracing using Fluorogold (FG; Invitrogen, Grand Island, NY, USA), 4 weeks after injury, 4% FG was injected into the YJ101 spinal cord compartment at four sites (0.5 μl per injection) per plane according to the following stereotaxic coordinates: (1) 0.5 mm medial-lateral (ML), 0.5 mm dorsal-ventral (DV); (2) 1.0 mM ML, 0.5 mm DV; (3) 0.5 mm ML, 2.0 mM DV; and (4) 1.0 mM ML, 2.0 mM DV. The dye was allowed to disperse for ≥2 min after each injection, and animals were sacrificed 1 week later for histological analysis. Transverse sections of 5-mm spinal cord slices containing the injection site were serially cut to confirm the extent of bulk injection, including the white matter, and to ensure that the dye did not diffuse beyond the injected spinal cord slice. Cases not meeting these criteria were excluded from further study. Transverse brain slices (40 μm thick) containing the sensorimotor cortex were cut on a cryostat, and every third slice was mounted on a glass slide. Ten sections per ret were analyzed, and the number of labeled neurons was counted per ret and averaged across the ret. Additionally, the expression profile of GAP43, a known axon regeneration factor, was confirmed by Western blot.
[0228] BDA anterograde axon tracing showed that the saline-transplanted and MSC-transplanted groups showed very little regeneration, whereas the ciNSC5-transplanted group showed extensive CST axon regeneration through and beyond the lesion cavity (Figure 53). Counting the number of axons showed that no axons were observed 1000 μm from the lesion cavity start in the saline-transplanted and MSC-transplanted groups, but axons were observed even at 2000 μm in the ciNSC5-transplanted group. Fluorogold retrograde axon tracing showed that the number of FG-labeled neurons was significantly higher in the ciNSC5-transplanted group than in the saline-treated control group in the RN, PnC, LVe, MdV, and MdD, whereas the MSC-transplanted group showed an increase in FG-labeled neurons only in the LVe, with no effect in other regions (Figure 54). Additionally, Western blot analysis showed that GAP43 expression in the spinal cord of the ciNSC5-transplanted group was significantly increased compared to the saline-transplanted group or the MSC-transplanted group (FIG. 55).
[0229] 7-5. Confirmation of differentiation into mature nerve cells Six weeks after transplantation of ciNSC5 into the chronic spinal cord injury model, immunohistochemical staining was carried out using human-specific STEM121 antibody.
[0230] As a result, STEM121-positive cells were observed near the transplantation site, which means that the transplanted ciNSC5 remained in the tissue. To confirm the cell type, double immunostaining was performed, which showed that the transplanted ciNSC5 were double-stained with the neuronal markers NeuN, MAP2, and Tuj1 (Figure 56). This suggests that the transplanted ciNSC5 differentiated into mature neurons in the spinal cord tissue.
Claims
1. A composition for inducing oligomerization of CtBPs (C-terminal Binding Proteins), comprising at least one selected from the group consisting of a compound represented by the following formula I, a compound represented by the following formula II, and a compound represented by the following formula III: 【Chemistry 1】
2. The composition for inducing oligomerization of CtBPs according to claim 1 , wherein the CtBPs is CtBP1 or CtBP2.
3. The composition for inducing oligomerization of CtBPs according to claim 1 , wherein the compound of formula I binds to Ser100 of CtBP1.
4. The composition for inducing oligomerization of CtBPs according to claim 1, wherein the compound of formula II binds to Ser100 and Arg266 of CtBP1.
5. The composition for inducing oligomerization of CtBPs according to claim 1, wherein the compound of formula 3 binds to Phe102, Arg184 and His236 of CtBP1.
6. The composition for inducing oligomerization of CtBPs according to claim 1, which mediates CtBPs-mediated differentiation of adult stem cells into neural progenitor cells.
7. A composition for inducing direct conversion of adult stem cells into neural progenitor cells, comprising at least one compound selected from the group consisting of a compound represented by formula I, a compound represented by formula II, and a compound represented by formula III.
8. The composition for direct transdifferentiation induction according to claim 7, wherein the adult stem cells are mesenchymal stem cells (MSCs).
9. The composition for direct transdifferentiation induction according to claim 8, wherein the mesenchymal stem cells are umbilical cord blood-derived mesenchymal stem cells (UCB-MSC), umbilical cord-derived mesenchymal stem cells (UC-MSC), adipose-derived mesenchymal stem cells (AD-MSC) or bone marrow-derived mesenchymal stem cells (BM-MSC).
10. The composition for direct transdifferentiation induction according to claim 7, wherein the neural progenitor cells are ciNSC5 (chemically induced neural stem cell 5).
11. The composition for direct transdifferentiation induction according to claim 7, which increases expression of Tuj1, TBR2, MASH1, GAP-43 or p75.
12. The composition for direct transdifferentiation induction according to claim 7, which increases expression of Tuj1 protein, CD325 (N-cadherin) protein, p75 protein, GAP-43 protein, CD54 protein, CD309 protein, CD56 (NCAM) protein, PSA-NCAM protein, CD29 protein, MASH1 protein or TBR2 protein.
13. The composition for direct transdifferentiation induction according to claim 7, which reduces expression of CD44, CD73 or CD105.
14. The composition for direct transdifferentiation induction according to claim 7, which increases the secretion of PlGF, NGF, BDNF, VEGFA, MMP1, MMP2, MMP7, TIMP2, SHH, Notch1, TNFSF12 or IL-16.
15. A method for inducing oligomerization of CtBPs, comprising the step of treating a sample in vitro with any one or more selected from the group consisting of a compound of formula I, a compound of formula II, and a compound of formula III.
16. The method for inducing oligomerization of CtBPs according to claim 15, wherein the sample is an adult stem cell.
17. 16. A method of inducing oligomerization of CtBPs according to claim 15, which increases Tuj1, CD325 (N-cadherin), p75, GAP-43, CD309, CD56 (NCAM), PSA-NCAM, CD29, MASH1 or TBR2 expression in a sample after compound treatment compared to before compound treatment.
18. 16. A method for inducing oligomerization of CtBPs as described in claim 15, which increases secretion of PlGF, NGF, BDNF, VEGFA, MMP1, MMP2, MMP7, TIMP2, SHH, Notch1, TNFSF12 or IL-16 in a sample after treatment with a compound compared to before treatment.
19. 16. The method of inducing oligomerization of CtBPs according to claim 15, which reduces expression of CD44, CD73 or CD105 in a sample after compound treatment compared to before treatment.
20. A method for inducing direct transdifferentiation of adult stem cells into neural progenitor cells, comprising the step of treating adult stem cells in vitro with one or more compounds selected from the group consisting of a compound of formula I, a compound of formula II, and a compound of formula III.
21. 21. The method of inducing direct transdifferentiation of claim 20, wherein the cells have increased Tuj1, CD325 (N-cadherin), p75, GAP-43, CD54, CD309, CD56 (NCAM), PSA-NCAM, CD29, MASH1 or TBR2 expression after compound treatment compared to before compound treatment.
22. 21. The method of inducing direct transdifferentiation of claim 20, wherein the secretion of PlGF, NGF, BDNF, VEGFA, MMP1, MMP2, MMP7, TIMP2, SHH, Notch1, TNFSF12 or IL-16 is increased in cells after treatment with the compound compared to before treatment.
23. 21. The method of inducing direct transdifferentiation of claim 20, wherein the expression of CD44, CD73 or CD105 is decreased in cells after compound treatment compared to before treatment.
24. Stem cells treated with one or more compounds selected from the group consisting of compounds of the following formula I, compounds of the following formula II, and compounds of the following formula III: 【Chemistry 2】
25. The stem cell of claim 24, wherein the compound-treated stem cell is an adult stem cell.
26. The stem cell according to claim 25, wherein the adult stem cell is umbilical cord blood-derived mesenchymal stem cells (UCB-MSC), umbilical cord-derived mesenchymal stem cells (UC-MSC), adipose-derived mesenchymal stem cells (AD-MSC) or bone marrow-derived mesenchymal stem cells (BM-MSC).
27. The stem cell according to claim 24, which has been treated in vitro with any one or more selected from the group consisting of a compound of formula I, a compound of formula II, and a compound of formula III for 3 to 7 days.
28. The stem cell according to claim 24, which has been subjected to direct conversion of an adult stem cell into a neural progenitor cell by treatment with a compound.
29. The stem cell according to claim 28, wherein the neural progenitor cell is ciNSC5 (chemically induced neural stem cell 5).
30. The stem cell of claim 24, which has increased expression of Tuj1, TBR2, MASH1, GAP-43 or p75 compared to stem cells not treated with the compound.
31. The stem cell of claim 24, wherein the expression of Tuj1 protein, CD325 (N-cadherin) protein, p75 protein, GAP-43 protein, CD54 protein, CD309 protein, CD56 (NCAM) protein, PSA-NCAM protein, CD29 protein, MASH1 protein or TBR2 protein is increased compared to stem cells not treated with the compound.
32. The stem cell of claim 24, wherein expression of CD44, CD73 or CD105 is decreased compared to stem cells not treated with the compound.
33. The stem cell of claim 24, which exhibits increased secretion of PlGF, NGF, BDNF, VEGFA, MMP1, MMP2, MMP7, TIMP2, SHH, Notch1, TNFSF12 or IL-16 compared to stem cells not treated with the compound.
34. The stem cell of claim 24, wherein expression of HES1, Sox2 or OCT4 is increased compared to stem cells not treated with the compound.
35. The stem cell according to claim 24, wherein oligomerization of CtBPs (C-terminal Binding Proteins) is induced by treatment with a compound.
36. The stem cell according to claim 24, which does not express MAP2, NSE, NeuN, doublecortin, NeuroD1 (Neurogenic differentiation 1), Nestin, Mussashi 1 or GFAP.
37. The stem cell of claim 24, which is capable of differentiating into a dopaminergic neuron, a neuron or a mature neuron.
38. A pharmaceutical composition for preventing or treating a nerve damage disease, comprising the stem cell, stem cell culture or suspension culture according to claim 24 as an active ingredient.
39. The pharmaceutical composition for preventing or treating a nerve damage disease according to claim 38, wherein the nerve damage disease is damage to the central or peripheral nervous system, or a neurodegenerative disease.
40. The pharmaceutical composition for preventing or treating a nerve damage disease according to claim 39, wherein the injury to the central or peripheral nervous system is spinal cord injury (SCI), traumatic brain injury (TBI), peripheral nerve injury, stroke or brain cancer.
41. The pharmaceutical composition for preventing or treating a nerve damage disease according to claim 39, wherein the neurodegenerative disease is Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), multiple sclerosis (MS) or multiple system atrophy.
42. Use of a compound of formula I, a compound of formula II or a compound of formula III for use in inducing oligomerization of CtBPs.
43. 20. Use of a compound of formula I, a compound of formula II or a compound of formula III for use in direct transdifferentiation induction.
44. A use of stem cells treated with one or more compounds selected from the group consisting of compounds of chemical formula I, compounds of chemical formula II, and compounds of chemical formula III for the prevention or treatment of nerve damage diseases.
45. A method for treating a nerve damage disease, comprising the step of transplanting stem cells treated with one or more compounds selected from the group consisting of a compound of chemical formula I, a compound of chemical formula II, and a compound of chemical formula III into an individual having the nerve damage disease.
Citation Information
Patent Citations
Ae source locating system and method thereof
KR1020200119565A
Composition for treating spinal cord injury, comprising stem cells treated with novel compound
WO2021100889A1
